Welcome to STN International! Enter x:x

LOGINID: ssspta1611sxp

PASSWORD:

* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * * * SESSION RESUMED IN FILE 'HOME' AT 13:18:23 ON 30 JUN 2003 FILE 'HOME' ENTERED AT 13:18:23 ON 30 JUN 2003

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 0.63 0.63

=> file req

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 0.63 0.63

FILE 'REGISTRY' ENTERED AT 13:18:37 ON 30 JUN 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4 DICTIONARY FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

 Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf


Uploading 10046526.1

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 13:19:04 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED

7 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

7 TO 298

PROJECTED ANSWERS:

O TO

L2

'0 SEA SSS SAM L1

=> s ll sss full

FULL SEARCH INITIATED 13:19:12 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L3

1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY SESSION

Patel

<6/30/2003>

10046526 Page 3

FULL ESTIMATED COST

148.15 148.78

FILE 'CAPLUS' ENTERED AT 13:19:17 ON:30 JUN 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1 FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13 L4 1 L3

=> d l4 fbib hitstr abs total

- L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
- AN 2002:539663 CAPLUS
- DN 137:109210
- TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
- PA Amgen Inc., USA
- SO PCT Int. Appl., 253 pp. CODEN: PIXXD2
- DT Patent
- LA English

FAN.CNT 1

| | PATENT NO. | | | | A2 20 | | DATE | | | APPLICATION NO. DATE | | | | | | | | | | |
|----|--------------------------------|-----|-----|----------------------|-------|-----|---------------|-----|-----|----------------------|------|------|-----|-----|-----|-----|-----|-----|--|--|
| PI | WO 2002055501 WO 2002055501 | | | 20020718 20021219 | | | WO 2002-US742 | | | | 2002 | 0111 | • . | | | | | | | |
| | | W : | | | | | | | | | | | | | BZ, | | | | | |
| | | | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | ES, | FI, | GB, | GD, | GE, | GH, | | |
| | | | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KΕ, | KG, | ΚP, | KR, | KZ, | LC, | LK, | LR, | | |
| | | | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MZ, | NO, | NZ, | OM, | PH, | | |
| | | | PL, | PT, | RO, | RU, | SD, | SE, | SG, | SI, | SK, | SL, | TJ, | TM, | TN, | TR, | TT, | TZ, | | |
| | | | UA, | UG, | UZ, | VN, | YU, | ZA, | ZW, | AM, | AZ, | BY, | KG, | KZ, | MD, | RU, | TJ, | TM | | |
| | | RW: | GH, | GM, | ΚE, | LS, | MW, | MZ, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | ΑT, | BE, | CH, | | |
| | | | CY, | DE, | DK, | ES, | FI, | FR, | GB, | GR, | ΙE, | IT, | LU, | MC, | NL, | PT, | SE, | TR, | | |
| | | | BF, | ВJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR; | NE, | SN, | TD, | TG | | |

IT

US 2002147198 **A1** 20021010 US 2001-261360PP 20010112 US 2001-323686PP 20010919 US 2002-46526 A 20020110 US 2002-46526 20020110 US 2001-261360PP 20010112

US 2001-323686PP 20010919

OS MARPAT 137:109210


442846-35-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442846-35-7 CAPLUS

3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-CN (1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)





GΙ

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un) substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un) substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N contg. linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-phenoxyaniline. Selected compds. of the invention, e.g., II, inhibited

10046526 Page 5

VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

| => d cost | · | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CONNECT CHARGES | 0.34 | 1.13 |
| NETWORK CHARGES | 0.06 | 0.30 |
| SEARCH CHARGES | 0.00 | 147.75 |
| DISPLAY CHARGES | 4.32 | 4.32 |
| | | |
| | 4.72 | 153.50 |
| CAPLUS FEE (5%) | 0.'23 | 0.23 |
| · | | |
| FULL ESTIMATED COST | 4.95 | 153.73 |
| | | |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| 63 GUDGGDUDDD DD GD | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | 0.65 | -0.65 |

IN FILE 'CAPLUS' AT 13:19:53 ON 30 JUN 2003

```
Welcome to STN International! Enter x:x
LOGINID: ssspta1611sxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
* * * * * * * * * *
                     Welcome to STN International
NEWS 1
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2
                 "Ask CAS" for self-help around the clock
                 New e-mail delivery for search results now available
NEWS 3 Jun 03
NEWS 4 Aug 08
                 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5 Aug 19
                 Aquatic Toxicity Information Retrieval (AQUIRE)
                 now available on STN
NEWS 6
         Aug 26
                 Sequence searching in REGISTRY enhanced
     7
NEWS
         Sep 03
                 JAPIO has been reloaded and enhanced
NEWS 8
         Sep 16
                 Experimental properties added to the REGISTRY file
NEWS 9
         Sep 16
                 CA Section Thesaurus available in CAPLUS and CA
NEWS 10 Oct 01
                 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11 Oct 24
                 BEILSTEIN adds new search fields
NEWS 12 Oct 24
                 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT
NEWS 14 Nov 25 More calculated properties added to REGISTRY
NEWS 15 Dec 04 CSA files on STN
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17 Dec 17
                 TOXCENTER enhanced with additional content
NEWS 18 Dec 17
                 Adis Clinical Trials Insight now available on STN
NEWS 19
         Jan 29
                 Simultaneous left and right truncation added to COMPENDEX,
                 ENERGY, INSPEC
NEWS 20 Feb 13
                 CANCERLIT is no longer being updated
NEWS 21 Feb 24 METADEX enhancements
NEWS 22 Feb 24 PCTGEN now available on STN
NEWS 23 Feb 24 TEMA now available on STN
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 25 Feb 26 PCTFULL now contains images
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27 Mar 20 EVENTLINE will be removed from STN
NEWS 28 Mar 24 PATDPAFULL now available on STN
NEWS 29 Mar 24
                 Additional information for trade-named substances without
                 structures available in REGISTRY
NEWS 30 Apr 11 Display formats in DGENE enhanced
NEWS 31 Apr 14 MEDLINE Reload
NEWS 32 Apr 17
                 Polymer searching in REGISTRY enhanced
NEWS 33 Jun 13
                 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34 Apr 21
                 New current-awareness alert (SDI) frequency in
                 WPIDS/WPINDEX/WPIX
NEWS 35 Apr 28
                 RDISCLOSURE now available on STN
                 Pharmacokinetic information and systematic chemical names
NEWS 36 May 05
                 added to PHAR
NEWS 37
         May 15
                 MEDLINE file segment of TOXCENTER reloaded
                 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 38
         May 15
```

May 16 CHEMREACT will be removed from STN

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA

NEWS 39

NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS 42 Jun 06 Simultaneous left and right truncation added to CBNB

NEWS 43 Jun 06 PASCAL enhanced with additional data

NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available

NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:25:55 ON 30 JUN 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

0.21

0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:26:04 ON 30 JUN 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4 DICTIONARY FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>


Uploading 10046526.2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 13:26:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2066 TO ITERATE

48.4% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

____,

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 38594 TO 44046 PROJECTED ANSWERS: 141 TO 685

L2 10 SEA SSS SAM L1

=> s l1 sss full FULL SEARCH INITIATED 13:26:33 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 40731 TO ITERATE

Patel

10 ANSWERS

100.0% PROCESSED 40731 ITERATIONS 255 ANSWERS

SEARCH TIME: 00.00.02

L3 255 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST ENTRY SESSION 148.15 148.36

FILE 'CAPLUS' ENTERED AT 13:26:41 ON 30 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1 FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 20 L3

=> d l4 fbib hitstr abs total

- L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS
- AN 2003:319701 CAPLUS
- DN 138:337840
- TI Preparation of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors
- IN Angell, Richard Martyn; Aston, Nicola Mary; Bamborough, Paul; Bamford,
 Mark James; Cockerill, George Stuart; Flack, Stephen Sean; Laine, Dramane
 Ibrahim; Merrick, Suzanne Joy; Smith, Kathryn Jane; Walker, Ann Louise
- PA Glaxo Group Limited, UK
- SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

- DT Patent
- LA English
- FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2003032971 A1 20030424 WO 2002-EP11576 20021016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

Patel <6/30/2003>

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,

GB 2001-24939 A 20011017

OS MARPAT 138:337840

IT 515812-31-4P 515812-32-5P 515812-34-7P 515812-35-8P 515812-44-9P

NE, SN, TD, TG

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors)

RN 515812-31-4 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(cyclopropylmethyl)amino]-N-[4'-[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)

RN 515812-32-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[4'-[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]-2-[(2-methylpropyl)amino]- (9CI) (CA INDEX NAME)

$$CH_2-NH-C$$
 $NH-C$
 $NHBu-i$

RN 515812-34-7 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclohexylamino)-N-[4'[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI)
(CA INDEX NAME)

RN 515812-35-8 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclopropylamino)-N-[4'[[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI)
(CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 515812-44-9 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclobutylamino)-N-[4'[(cyclopropylmethyl)amino]carbonyl]-6-methyl[1,1'-biphenyl]-3-yl]- (9CI)
(CA INDEX NAME)

GI

$$\begin{bmatrix} U \end{bmatrix}_{S} = \begin{bmatrix} R^{2} \\ V \end{bmatrix}_{M} = \begin{bmatrix} CH_{2} \end{bmatrix}_{M} = \begin{bmatrix} H \\ V \end{bmatrix}_{$$

AB The title compds. [I; when m = 0-4, R1 = alkyl, cycloalkyl, alkenyl, etc.;
when m = 2-4, R1 addnl. = alkoxy, OH, etc.; R2 = H, alkyl,
 (CH2)ncycloalkyl; R3 = NHCOR6 (wherein R6 = H, alkyl, alkoxy, etc.); U =
 Me, halo; W = Me, Cl; X, Y = H, Me, halo; m = 0-4; n = 0-1; s = 0-2],
 useful as pharmaceuticals, particularly as p38 kinase inhibitors, were
 prepd. E.g., a 6-step synthesis of the nicotinamide II, starting with
 3-bromo-4-methylaniline, was given.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2003 ACS
```

AN 2003:261670 CAPLUS

DN 138:287666

TI Preparation of heteroaryllactams as Factor Xa inhibitors

IN Pinto, Donald; Quan, Mimi; Orwat, Michael; Li, Yun-Long; Han, Wei; Qiao, Jennifer; Lam, Patrick; Koch, Stephanie

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 441 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. _ _ _ _ _____ PΙ WO 2003026652 20030403 WO 2002-US29491 A1 20020917 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2001-324165PP 20010921

OS MARPAT 138:287666

IT 503613-25-0P, 2-[(4-Chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]nicotinamide

RN

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compd.; prepn. of heteroaryllactams as Factor Xa inhibitors) 503613-25-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-chlorobenzoyl)amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)

AΒ P4PMM4 [M = 3-10 membered (substituted) (unsatd.) carbocyclyl, 4-10 membered heeterocyclyl; P = null, 5-7 membered (substituted) (unsatd.) carbocyclyl, heterocyclyl fused to ring M; 1 of P4, M4 = ZAB, the other = GlG; G = (benzo-, pyrido-, pyrimido-, pyrazino-, or pyridazino-fused) (substituted) (unsatd.) 5-6 membered (hetero)cyclyl; Gl = null, (CR3R3a)1-5, etc.; R3, R3a = H, Me, Et, Pr, Ph, PhCH2, etc.; Z = bond, (CR3R3e)1-4, etc.; R3e = H, SO2NHR3, SO2N(R3)2, COR3, (substituted) alkyl, alkenyl, alkynyl, etc.; A = (substituted) 3-10 membered carbocyclyl, 5-12 membered heterocyclyl; Z = XNQ; X = null, CO, SO, SO2, etc.; NQ = 4-8 membered mono- or bicyclic (substituted) (unsatd.) ring contg. a CO or SO2 group adjacent to the N atom; with provisos], were prepd. Thus, 6-(4-iodophenyl)-3-methoxy-1-(4-methoxyphenyl)-1,4,5,6-tetrahydro-7Hpyrazolo[3,4-c]pyridin-7-one (prepn. given), .delta.-valerolactam, K2CO3, and CuI were refluxed in Me2SO to give 15% 3-methoxy-1-(4-methoxyphenyl)-6-[4-(2-oxo-1-piperidinyl)phenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4c]pyridin-7-one. Several title compds. inhibited Factor Xa with IC50.ltoreq. 10 .mu.M.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2003:22869 CAPLUS

DN 138:89806

TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.

IN Ingraham, Richard H.; Proudfoot, John R.

PA Boehringer Ingelheim Pharmaceuticals Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN. CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

PΙ WO 2003002555 A1 20030109 WO 2002-US18752 20020614 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2001-302066PP 20010629 US 2003022929 A 1 20030130 US 2002-172457 20020614 US 2001-302066PP 20010629

OS MARPAT 138:89806

IT 251656-70-9P 251656-71-0P 483342-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylpyrazoles as sol. epoxide hydrolase inhibitors for treatment of cardiovascular disease)

RN 251656-70-9 CAPLUS

CN

3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

RN 251656-71-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

RN 483342-21-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

IT 251656-99-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of arylpyrazoles as sol. epoxide hydrolase inhibitors for treatment of cardiovascular disease)

RN 251656-99-2 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(2-hydroxyethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ N & & & \\ \hline \\ CF_3 & & \\ \end{array}$$

GI

$$R^2$$
 N
 LR^4
 R^3
 R^3
 R^3
 R^3
 R^3
 R^3
 R^3

AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2002:676007 CAPLUS

DN 137:216945

TI Preparation of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases

IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang; Kim, Tae-Seong

PA Amgen Inc., USA

SO PCT Int. Appl., 395 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATEŅT | KI | ND | DATE | | | A | PPLI | CATI | ο. | DATE | | | | | | | | |
|----|---------------|-----------|-----|------|-----|----------|-----|-----------------------------|------|---------------------------|--------------------------|------|-----|----------|-----|-----|-----|--|--|
| | | | | | | · | | | _ | | | | | | | | | | |
| PI | WO 2002068406 | | | A2 | | 20020906 | | | W | 20 | 02-U | 5306 | 4 | 20020111 | | | | | |
| • | WO 2002 | 002068406 | | | 3 | 20030424 | | , | | | | | | | | | | | |
| | W : | ΑE, | AG, | AL, | AM, | ΑT, | AU, | ΑZ, | BA, | BB, | BG, | BR, | BY, | ΒZ, | CA, | CH, | CN, | | |
| | • | | | | | | | | | | | | | GB, | | | | | |
| | | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KΕ, | KG, | KP, | KR, | ΚZ, | LC, | LK, | LR, | | |
| | | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MZ, | NO, | NZ, | OM, | PH, | | |
| | | PL, | PT, | RO, | RU, | SD, | SE, | SG, | SI, | SK, | SL, | TJ, | TM, | TN, | TR, | TT, | TZ, | | |
| | | | | | | | | | | | | | | MD, | | | | | |
| | RW: | GH, | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | NL, | | | | | |
| | | ₿F, | ΒJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | NE, | SN, | TD, | TG | | |
| | | | | | | | | US 2001-261882PP 20010112 · | | | | | | | | | | | |
| | | | | | | | | | | US-2001-323808PP 20010919 | | | | | | | | | |
| | | | | | | | | | | | US 2002-46622 A 20020110 | | | | | | | | |

OS MARPAT 137:216945

IT 454480-74-1P 454481-80-2P 454481-82-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for treating KDR-related diseases)

RN 454480-74-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-80-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-82-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2-hydroxyethyl)amino]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

```
IT
     454480-71-8P 454480-73-0P 454480-77-4P
     454480-81-0P 454480-86-5P 454480-87-6P
     454480-88-7P 454480-89-8P 454480-90-1P
     454480-95-6P 454480-97-8P 454480-98-9P
     454481-00-6P 454481-07-3P 454481-12-0P
     454481-17-5P 454481-20-0P 454481-21-1P
     454481-22-2P 454481-23-3P 454481-24-4P
     454481-26-6P 454481-28-8P 454481-30-2P
     454481-31-3P 454481-32-4P 454481-33-5P
     454481-34-6P 454481-35-7P 454481-45-9P
     454481-46-0P 454481-47-1P 454481-48-2P
     454481-49-3P 454481-50-6P 454481-51-7P
     454481-52-8P 454481-53-9P 454481-55-1P
     454481-60-8P 454481-62-0P 454481-63-1P
     454481-65-3P 454481-69-7P 454481-70-0P
     454481-75-5P 454481-76-6P 454481-77-7P
     454481-78-8P 454481-79-9P 454481-83-5P
     454481-84-6P 454481-89-1P 454481-90-4P
     454481-99-3P 454482-04-3P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for
        treating KDR-related diseases)
RN
     454480-71-8 CAPLUS
CN
     3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(1-
     methylethyl)phenyl] - (9CI) (CA INDEX NAME)
```

Patel

10046526 .2

Page 14

RN 454480-73-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(1-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454480-77-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-benzotriazol-5-ylamino)-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454480-81-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(1,2-dihydro-4-methyl-2-oxo-7-quinolinyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454480-86-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(nonafluorobutyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454480-87-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(1-methyl-1H-indazol-6-yl)amino]- (9CI) (CA INDEX NAME)

RN 454480-88-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(7-bromo-1H-indazol-6-yl)amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454480-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454480-90-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-(4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 454480-95-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[(1S)-1-aminoethyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454480-97-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[(1S)-1-[(1-methylethyl)amino]ethyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 454480-96-7 CMF C24 H26 N6 O

Absolute stereochemistry.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 454480-98-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-methyl-1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-2-(4-methyl-1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-07-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-[2-(dimethylamino)ethoxy]-1H-indazol-6-yl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

$$O-CH_2-CH_2-NMe_2$$

RN 454481-12-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,1'-biphenyl]-4-yl-2-(1H-indazol-6-ylamino)-(9CI) (CA INDEX NAME)

RN 454481-17-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-{4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-20-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(1-methyl-4-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-21-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-piperidinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-22-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1E)-4-(1-pyrrolidinyl)-1-butenyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 454481-23-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-pyrrolidinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-24-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(4-morpholinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX

10046526 .2

Page 22

NAME)

RN 454481-26-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 454481-28-8 CAPLUS

CN

3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[3-(4-methyl-1-piperazinyl)propyl]phenyl]- (9CI) (CA INDEX NAME)

RN 454481-30-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-3-(4-morpholinyl)propyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

PAGE 2-A



RN 454481-31-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[2,2,2-trifluoro-1-[2-(2-methoxyethoxy)ethoxy]-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 454481-32-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[2,2,2-trifluoro-1-[2-(2-methoxyethoxy)ethoxy]-1-(trifluoromethyl)ethyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 454481-31-3 CMF C27 H25 F6 N5 O4

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 454481-33-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[2,2,2-trifluoro-1-[2-(1-piperidinyl)ethoxy]-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

N

RN 454481-34-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-6-fluoro-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-fluoro-2-(1H-indazol-6-ylamino)-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-45-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[(1-methyl-4-piperidinyl)methoxy]-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

$$CH_2-O$$
 F_3C-CF_2

RN 454481-46-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[[1-(1-methylethyl)-4-piperidinyl]methoxy]-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

$$CH_2-O$$
 F_3C-CF_2

RN 454481-47-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454481-48-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Patel <6/30/2003>

$$O-CH_2-CH_2$$
 NH
 F_3C-CF_2

RN 454481-49-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454481-50-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454481-51-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454481-52-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[(2R)-2- · pyrrolidinylmethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454481-53-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-55-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 454481-60-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

$$CH_2-O$$
 $t-Bu$

RN 454481-62-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454481-63-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 454481-65-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-69-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-propyl-1-piperazinyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-70-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[4-(1-methylethyl)-1-piperazinyl]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-75-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-[(4-methyl-1-piperazinyl)methyl]-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-76-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenyl]methyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 454481-77-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[3-(4-morpholinylmethyl)-4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-78-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)-3-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-79-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-(1,1-dimethylethyl)-5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 454481-83-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

$$O = C$$

$$N = CH_2 - CH_2 - NH$$

$$t - Bu$$

RN 454481-84-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-(1H-indazol-6-ylamino)-3-pyridinyl]carbonyl]amino]phenyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 454481-89-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1H-indazol-6-ylamino)-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 454481-90-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylamino)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

RN 454481-99-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)-1-propynyl]-4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylámino)- (9CI) (CA INDEX NAME)

RN 454482-04-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

IT 454481-81-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for
 treating KDR-related diseases)

RN 454481-81-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-amino-4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

IT 454482-08-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
 (prepn. of substituted 2-(1H-indazol-6-ylamino)nicotinamides for
 treating KDR-related diseases)

RN 454482-08-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(2-bromoethyl)amino]-4-(1,1-dimethylethyl)phenyl]-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)

GI

AB The title compds. [I; each of A1 and A2 = C, CH, N; A = 5-6 membered partially satd. heterocyclyl, 5-6 membered heteroaryl, 9-11 membered fused partially satd. heterocyclyl, etc.; X = C(:Z)N(R5a)R4; Z = O, S; R = (un)substituted 4-6 membered heterocyclyl, aryl, fused 9-14 membered bicyclic or tricyclic heterocyclyl; R1 = (un)substituted 6-10 membered aryl, 4-6 membered heterocyclyl, cycloalkyl, etc.; R2 = H, halo, cycloalkyl, etc.; R4 = a bond, alkylene, alkenylene, etc.; R5 = H, alkyl, (un)substituted Ph, aralkyl; R5a is not defined] which are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases, were prepd. Thus, heating N-(4-chlorophenyl)-2-chloro-3-pyridinecarboxamide with 6-aminoindazole at 150.degree. for 2 h afforded II which inhibited VEGF-stimulated HUVEC proliferation at level below 50 nM. Compds. I showed inhibition of KDR at doses less than 50 .mu.M.

- L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS
- AN 2002:658116 CAPLUS
- DN 137:201332
- TI Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases
- IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel;

Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang

PA Amgen Inc., USA

SO PCT Int. Appl., 502 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. DATE KIND APPLICATION NO. DATE _____ PΙ WO 2002066470 A1 20020829 WO 2002-US743 20020111 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2001-261339PP 20010112 US 2001-323764PP 20010919 US 2002-46681 A 20020110

OS MARPAT 137:201332

IT 453561-73-4P 453561-77-8P 453561-95-0P 453562-83-9P 453563-79-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453561-73-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-5-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-77-8 CAPLUS

RN 453561-95-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-83-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(2-chloro-4-pyridinyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-79-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[1-(diphenylmethyl)-3-azetidinyl]oxy]-4-pyridinyl]methyl]amino]- (9CI) (CA

INDEX NAME)

```
IT
     352227-65-7P 352227-74-8P 453561-12-1P
     453561-21-2P 453561-29-0P 453561-33-6P
     453561-38-1P 453561-72-3P 453561-76-7P
     453561-78-9P 453561-80-3P 453561-83-6P
     453561-87-0P, (S)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-
    pentafluoroethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide
     453561-88-1P, (R)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-
     trifluoromethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide
     453561-89-2P, (R)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-
    pentafluoroethylphenyl] -2-[(pyridin-4-ylmethyl)amino]nicotinamide
     453561-93-8P, N-[4-tert-Butyl-3-[(piperidin-4-yl)methoxy]phenyl]-2-
     [(pyridin-4-ylmethyl)amino]nicotinamide 453561-94-9p,
    N-[4-tert-Butyl-3-(pyrrolidin-2-ylmethoxy)phenyl]-2-[(pyridin-4-
    ylmethyl)amino]nicotinamide 453561-96-1P 453561-98-3P
     453562-02-2P 453562-03-3P 453562-05-5P
    453562-20-4P 453562-21-5P 453562-23-7P
     453562-29-3P 453562-52-2P 453562-56-6P
     453562-76-0P 453562-80-6P 453562-84-0P
     453562-85-1P 453562-87-3P 453562-91-9P
     453562-92-0P 453562-93-1P 453562-96-4P
     453563-02-5P 453563-06-9P 453563-08-1P
     453563-10-5P 453563-15-0P 453563-17-2P
     453563-18-3P 453563-20-7P 453563-22-9P
     453563-23-0P 453563-24-1P 453563-25-2P
     453563-27-4P 453563-29-6P 453563-32-1P
     453563-33-2P 453563-38-7P 453563-39-8P
     453563-40-1P 453563-41-2P 453563-45-6P
     453563-46-7P 453563-47-8P 453563-50-3P
     453563-51-4P 453563-54-7P 453563-55-8P
     453563-56-9P 453563-58-1P 453563-61-6P
     453563-63-8P 453563-65-0P 453563-67-2P
     453563-68-3P 453563-70-7P 453563-81-0P
     453563-84-3P 453563-85-4P 453563-86-5P
     453563-87-6P 453563-88-7P 453563-89-8P
     453563-90-1P 453563-91-2P 453563-92-3P
     453563-93-4P 453563-94-5P 453563-99-0P
     453564-00-6P 453564-03-9P 453564-04-0P
```

453564-06-2P 453564-11-9P 453564-13-1P

453564-14-2P 453564-15-3P 453564-34-6P 453564-36-8P 453564-42-6P 453564-45-9P 453564-67-1P 453564-68-6P 453564-66-4P 453564-67-5P 453564-68-6P 453564-69-7P 453564-70-0P 453564-71-1P 453564-84-6P 453564-85-7P 453564-86-8P 453564-92-6P 453564-94-8P 453564-99-3P 453565-02-1P 453565-03-2P 453565-15-6P 453565-17-8P 453565-25-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 352227-65-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-butylphenyl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)

RN 352227-74-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-12-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-6-methyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-21-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-29-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-33-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 453561-38-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(4-hydroxybutyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-72-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-76-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(4-morpholinylmethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-78-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(2-aminoethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

$$H_2N-CH_2-CH_2$$
 $NH-C$
 NH

RN 453561-80-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453561-83-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-(1-piperazinylmethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-87-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453561-88-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453561-89-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453561-93-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-94-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-96-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-amino-4-(1,1-dimethylethyl)phenyl]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453561-98-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-02-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-03-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(nonafluorobutyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-05-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]- (9CI) (CA INDEX NAME)

RN 453562-20-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylpropyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-21-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-methylphenyl)-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)

RN 453562-52-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-methyl-1-piperazinyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-56-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(4-methyl-1-piperazinyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-76-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-3-(4-morpholinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ N - CH_2 - CH_2 - C \\ & & \\ Me \end{array} \qquad \begin{array}{c} Me \\ NH - C \\ NH - C \\ \end{array}$$

RN 453562-80-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[(1-methyl-4-piperidinyl)methoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453562-84-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(dimethylamino)-1-propynyl]-4-pyridinyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453562-85-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(2-methoxy-4-pyridinyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453562-87-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-piperidinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-91-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(1-pyrrolidinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-92-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1E)-4-(1-pyrrolidinyl)-

Patel

1-butenyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)
Double bond geometry as shown.

RN 453562-93-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[3-(4-morpholinyl)propyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453562-96-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-02-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-[2-(dimethylamino)ethoxy]ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-06-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1-(2-cyclohexylethoxy)-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-08-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-6-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-10-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-15-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,1'-biphenyl]-4-yl-2-[(4-pyridinylmethyl)amino]-(9CI) (CA INDEX NAME)

RN 453563-17-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-cyclohexylphenyl)-2-[(4-pyridinylmethyl)amino]-, trihydrochloride (9CI) (CA INDEX NAME)

●3 HCl

RN 453563-18-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-2-[(4-pyridinylmethyl)amino]-, trihydrochloride (9CI) (CA INDEX NAME)

●3 HCl

RN 453563-20-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(4-morpholinyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)

•x HCl

RN 453563-22-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-(trifluoromethyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

•x HCl

RN 453563-23-0 CAPLUS
CN Benzoic acid, 4-[[[2-[(4-pyridinylmethyl)amino]-3pyridinyl]carbonyl]amino]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

•x HCl

RN 453563-24-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-25-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-27-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-29-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[[1-(1-methylethyl)-3-azetidinyl]methoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-32-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[1-(1-methylethyl)-3-azetidinyl]methoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

10046526 .2

Page 63

RN 453563-33-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 453563-38-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(1-methyl-4-piperidinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-39-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} N & Me \\ \hline N & NH-CH_2 \\ \hline \end{array}$$

RN 453563-40-1 CAPLUS

CN · 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[[[2-[2-(2-pyrrolidinyl)ethoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453563-41-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[2-(2-pyrrolidinyl)ethoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453563-45-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(4-methyl-1-piperazinyl)methyl]-4(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

$$CH_2$$
 NH
 CH_2
 CH

RN 453563-46-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(pentafluoroethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

$$CH_2$$
 CH_2
 CH_2

RN 453563-47-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(1-methyl-4-piperidinyl)propoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-50-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(4-morpholinyl)propoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-51-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 M_{e}
 M_{e}
 M_{e}
 M_{e}

RN 453563-54-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[3-(4-morpholinyl)propoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453563-55-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453563-56-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-58-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-61-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453563-63-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 453563-65-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyl)methoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-67-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453563-68-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453563-70-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]methyl]amino]- (9CI). (CA INDEX NAME)

RN 453563-81-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[2-(1-methyl-4-piperidinyl)ethoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453563-84-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 453563-85-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453563-86-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(2S)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453563-87-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-methyl-4-piperidinyl)methoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-88-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(1-methyl-4-piperidinyl)methoxy]-4-(pentafluoroethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[2-(1-piperidinyl)ethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-90-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[2-(1-piperidinyl)ethoxy]-4-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453563-91-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(pentafluoroethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453563-92-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]-2-(trifluoromethyl)phenoxy]methyl]-,-1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453563-93-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(pentafluoroethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453563-94-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[(1-methyl-4-piperidinyl)oxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

RN 453563-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 453564-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-methyl-3-azetidinyl)methoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453564-03-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453564-04-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(2-methoxy-4-pyridinyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 453564-06-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(dimethylamino)propoxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

$$V_{\rm NH-C}$$
 $V_{\rm NH-C}$ $V_{\rm NH-C}$ $V_{\rm NH-C}$

RN 453564-11-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

$$\bigcap_{F_3C} N - CH_2 - CH_2 - O - NH - C - NH$$

RN 453564-13-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 453564-14-2 CAPLUS

CN Benzeneacetic acid, .alpha., alpha.-dimethyl-4-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 453564-15-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453564-34-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 453564-36-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-(3-azetidinyloxy)-4-pyridinyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453564-42-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 453564-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 453564-47-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

RN 453564-48-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

RN 453564-66-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-[2,2,2-trifluoro-1-[2-(1-piperidinyl)ethoxy]-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 453564-67-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[1,1'-biphenyl]-4-yl-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)

•x HCl

RN 453564-68-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-cyclohexylphenyl)-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)

•x HCl

RN . 453564-69-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(7-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

$$O = C$$

$$NH - CH_2$$

$$NH - CH_2$$

$$L - Bu$$

RN 453564-70-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2-ethyl-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 453564-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyl)methoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453564-84-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyl)oxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453564-85-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyl)oxy]-4-pyridinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453564-86-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[(1-methyl-2-pyrrolidinyl)methoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

10046526 .2

Page 86

$$\begin{array}{c} N \\ N \\ NH \\ CH_2 \\ \hline \\ NH \\ \hline \\ t-Bu \\ \end{array}$$

RN 453564-92-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-[3-(1-methyl-4-piperidinyl)propoxy]-4-pyridinyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453564-94-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[3-(1-methyl-4-piperidinyl)propoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)

10046526 .2

Page 87

RN 453564-99-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[2-(1,1-dimethylethyl)-5-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 453565-02-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylpropyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

RN 453565-03-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

RN 453565-09-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[2-(1-piperidinyl)ethoxy]phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI)- (CA INDEX NAME)

RN 453565-10-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & \\ & & & & \\ & & & & \\ & & & \\ N & & CH_2 - CH - CH_2 - O \\ & & & \\ & & & \\ F_3C - CF_2 \end{array}$$

RN 453565-11-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(1-methyl-4-piperidinyl)methoxy]-4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 453565-15-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)-2-(3-pyridinyl)ethyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 453565-17-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[(4-methyl-1-piperazinyl)methyl]-4-(pentafluoroethyl)phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]-(9CI) (CAINDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 453565-25-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

IT 453561-74-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of heterocyclylalkylamine derivs. as remedies for angiogenesis
 mediated diseases)

RN 453561-74-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

IT 453561-30-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453561-30-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)

•x HCl

GΙ

$$R^{2} = \begin{bmatrix} A^{1} - XR^{1} \\ A^{1} - YR \end{bmatrix}$$

AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially satd. heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially satd. heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un) substituted aryl, 5-, or 6-membered (un) substituted heterocyclyl, 9-11 membered (un) substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepd. and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compd. II was prepd. from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS
- AN 2002:628768 CAPLUS
- DN 138:130777
- TI Synthesis and study of antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines
- AU Pavlova, M. V.; Mikhalev, A. I.; Kon'shin, M. E.; Vasil'eva, M. Yu.; Mardanova, L. G.; Odegova, T. F.; Vakhrin, M. I.
- CS State Pharmaceutical Academy, Perm, Russia
- SO Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2001), 35(12), 664-666 CODEN: PCJOAU; ISSN: 0091-150X
- PB Kluwer Academic/Consultants Bureau

DT Journal

LA English

IT 491832-89-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines)

RN 491832-89-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-acetylphenyl)-2-[[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

AB The compds. 2-(4-sulfamylanilino)nicotinic acid amides were synthesized by heating 2-chloronicotinic acid amides with p-aminosulfanylamides in 50% acetic acid. The desired 2-aryloxynicotinic acid amides were prepd. via interaction of 2-chloronicotinic acid amides with phenols in DMF in the presence of anhyd. potassium carbonate. The antimicrobial and antiinflammatory activity of these synthesized compds. were evaluated. The antiinflammatory effect of these compds. was only slightly lower compared to that or ortophen, and some of the compds. also displayed a weak antimicrobial effect.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 2002:539663 CAPLUS

DN 137:109210

TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents

IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro,
Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim,
Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker,
Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenquang

PA Amgen Inc., USA

SO PCT Int. Appl., 253 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | | | | KIND | | DATE | | | APPLICATION NO. | | | | | DATE | | | |
|----|---------------|------------|-----|-------------|------|-----|----------|---------------------------|-----|---------------------------|------|------|------|-----|----------|------|-----|-----|
| | | | | | | | | | | | | | | | | | | |
| PI | WO | 2002055501 | | | A2 | | 20020718 | | | WO 2002-US742 | | | | | 20020111 | | | |
| | WO | 2002055501 | | | A3 | | 20021219 | | | | | | | | | | | |
| | | W : | ΑE, | AG, | AL, | AM, | ΑT, | AU, | AZ, | BA, | BB, | BG, | BR, | BY, | BZ, | CA, | CH, | CN, |
| | | | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | ES, | FI, | GB, | GD, | GE, | GH, |
| | | | GM, | HR, | HU, | ID, | ΙL, | IN, | IS, | JP, | KE, | KG, | ΚP, | KR, | KZ, | LC, | LK, | LR, |
| | | | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MZ, | NO, | NZ, | OM, | PH, |
| | | | PL, | ΡŤ, | RO, | RU, | SD, | SE, | SG, | SI, | SK, | SL, | TJ, | TM, | TN, | TR, | TT, | TZ, |
| | | | UA, | UG, | UZ, | VN, | YU, | ZA, | ZW, | AM, | AZ, | BY, | KG, | ΚŻ, | MD, | RU, | TJ, | TM |
| | | RW: | GH, | GM, | KΕ, | LS, | MW, | MZ, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AT, | BE, | CH, |
| | | | CY, | DE, | DK, | ES, | FI, | FR, | GB, | GR, | ΙE, | ΙT, | LU, | MC, | NL, | PT, | SE, | TR, |
| | | | BF, | ВJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | NE, | SN, | TD, | TG |
| | | | | | | | | US 2001-261360PP 20010112 | | | | | | | | | | |
| | | | | | | | | | | US 2001-323686PP 20010919 | | | | | | | | |
| | | | | | | | | | | US 2002-46526 A 20020110 | | | | | | | | |
| | US 2002147198 | | | A1 20021010 | | | | US 2002-46526 20020110 | | | | | | | | | | |
| | • | | | | | | | | | US 2001-261360PP 2001011 | | | | | | 0112 | | |
| | | | | | | | | | | U: | S 20 | 01-3 | 2368 | 6PP | 2001 | 0919 | | |

OS MARPAT 137:109210

IT 442845-74-1P 442846-13-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442845-74-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 442846-13-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 442845-75-2P 442845-86-5P 442845-87-6P
442845-88-7P 442845-89-8P 442845-90-1P
442846-04-0P 442846-06-2P 442846-07-3P
442846-09-5P 442846-12-0P 442846-14-2P
442846-21-1P 442846-24-4P 442846-26-6P
442846-27-7P 442846-35-7P 442846-37-9P
442846-40-4P 442846-42-6P 442846-44-8P
442846-46-0P 442846-48-2P 442846-52-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
 (target compd.; prepn. of substituted aminopyridines as antitumor
 agents)

RN 442845-75-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[(4-methoxyphenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 442845-86-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(2-

methylpropyl)phenyl] - (9CI) (CA INDEX NAME)

RN 442845-87-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 442845-88-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 442845-89-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 442845-90-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 442846-04-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 442846-06-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 442846-07-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 442846-09-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 442846-12-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 442846-14-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 442846-21-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 442846-24-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 442846-26-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 442846-27-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CAINDEX NAME)

Absolute stereochemistry.

RN 442846-35-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

RN 442846-37-9 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid, .beta.-[[3-[[4-(pentafluoroethyl)phenyl]amino]carbonyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & &$$

RN 442846-40-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

RN 442846-42-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 442846-44-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-piperidinylmethyl)amino]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 442846-46-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 442846-48-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-(2-pyrrolidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

RN 442846-52-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{CH}_2\\ \text{CH}_2\\ \text{O}\\ \text{NH}\\ \text{CH}_2-\text{O}\\ \end{array}$$

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form AB part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un) substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un) substituted aryl; R4 = H, alkyl, (un) substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N contg. linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepd. and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-phenoxyaniline. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

```
L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS
```

AN 2001:587254 CAPLUS

DN 135:166826

TI Preparation of pyrazoles as calcium channel inhibitors

IN Kubota, Koichi; Yonetoku, Yasuhiro; Okamoto, Yoshinori; Ishikawa, Atsushi; Takeuchi, Makoto

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

Patel

GI

<6/30/2003>



PI JP 2001220390 A2 20010814 JP 2000-31493 20000209 JP 2000-31493 20000209

OS MARPAT 135:166826

IT 353457-98-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazoles as calcium channel inhibitors)

RN 353457-98-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(2-methylpropyl)amino]-N-[4-[4,5,6,7-tetrahydro-3-(trifluoromethyl)-1H-indazol-1-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

GΙ

AB Title compds. I [one of Ra and Rb = H, lower alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Rb and the other substitute of Ra and Rc form (un)substituted C3-6 alkylene, alkenylene; B = (un)substituted phenylene; A = (un)substituted aryl; monocyclic or dicyclic heteroaryl] or their pharmaceutically acceptable salts are prepd. 4-(3-Trifluoromethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)aniline (563 mg) was reacted with 356 mg nicotinoyl chloride hydrochloride in the presence of Et3N in THF at room temp. for 13 h to give 438 mg 4'-(3-trifluoromethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl)nicotinanilide hydrochloride.

- L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS
- AN 2001:565010 CAPLUS
- DN 135:137407
- TI Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors
- IN Manley, Paul William; Bold, Guido
- PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
- SO PCT Int. Appl., 66 pp. CODEN: PIXXD2

'DT Patent LΑ English FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE ---------PΙ WO 2001055114 Α1 20010802 WO 2001-EP835 20010125 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG GB 2000-1930 A 20000127 BR 2001007805 Α 20021022 BR 2001-7805 20010125 GB 2000-1930 A 20000127 WO 2001-EP835 W 20010125 EP 2001-946854 EP 1259487 A1 20021127 20010125 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR GB 2000-1930 A 20000127 WO 2001-EP835 W 20010125 NO 2002003218 20020916 Α NO 2002-3218 20020702 A 20000127 GB 2000-1930 WO 2001-EP835 W 20010125 US 2003032656 A 1 20030213 US 2002-181005 20020711

OS MARPAT 135:137407

IT 352227-88-4P 352227-89-5P 352227-97-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

GB 2000-1930

WO 2001-EP835 W 20010125

A 20000127

(prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)

RN 352227-88-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 352227-89-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 352227-97-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

IT 352227-61-3P 352227-64-6P 352227-65-7P

352227-69-1P 352227-70-4P 352227-74-8P

352227-90-8P 352227-96-4P 352227-98-6P

352228-07-0P 352228-08-1P 352228-09-2P

352228-10-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)

RN 352227-61-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 352227-64-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-propylphenyl)-2-[(4-pyridinylmethyl)amino](9CI) (CA INDEX NAME)

RN 352227-70-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-propynyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 352227-74-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 352227-90-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 352227-96-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 352227-98-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-propyl-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 352228-07-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(1-oxido-4-pyridinyl)methyl]amino]-N-[4-propyl-

3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 352228-08-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-ethyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 352228-09-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

RN 352228-10-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

GI

$$\begin{array}{c|c}
W \\
NR^{1}R^{2} \\
N \\
R^{3} \\
CRR \\
T \\
X I
\end{array}$$

AB The title compds. [I; n = 1-6; W = 0, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R'

= H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = 0; R1, R3 = H; R2 = 3-(F3C)C6H4].

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L4
     ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS
AN
     2000:227634 CAPLUS
DN
     132:265091
ΤI
     Preparation of N-(benzamidophenyl)pyridinecarboxamides and analogs as
     cytokine production inhibitors
IN
     Brown, Dearg Sutherland; Brown, George Robert
PA
     Zeneca Limited, UK
SO
     PCT Int. Appl., 138 pp.
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                          APPLICATION NO.
                                                           DATE
                      _ _ _ _
                           _____
                                          -----
PΙ
     WO 2000018738
                     A1 20000406
                                          WO 1999-GB3144
                                                          19990921
         W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                          GB 1998-20770 A 19980925
                                           GB 1998-26938 A 19981209
                                           GB 1999-5969
                                                         A 19990317
     CA 2340454
                      AA
                           20000406
                                           CA 1999-2340454 19990921
                                           GB 1998-20770 A 19980925
                                           GB 1998-26938 A 19981209
                                           GB 1999-5969
                                                         A 19990317
                                           WO 1999-GB3144 W 19990921
    AU 9961034
                      A1
                           20000417
                                           AU 1999-61034
                                                           19990921
                                           GB 1998-20770 A 19980925
                                           GB 1998-26938 A 19981209
                                           GB 1999-5969
                                                         A 19990317
                                          WO 1999-GB3144 W 19990921
    BR 9913947
                      Α
                           20010612
                                           BR 1999-13947
                                                           19990921
                                          GB 1998-20770 A 19980925
                                          GB 1998-26938 A 19981209
                                          GB 1999-5969
                                                         A 19990317
                                          WO 1999-GB3144 W 19990921
     EP 1115707
                      A1
                           20010718
                                           EP 1999-947653
                                                           19990921
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO .
                                          GB 1998-20770 A 19980925
```

| | | | GB GB | 1998-26938 1999-5969 | A A | 19981209 19990317 |
|---------------|----|----------|----------|-------------------------|--------|----------------------|
| | | | WO | 1999-GB3144 | W | 19990921 |
| JP 2002525358 | T2 | 20020813 | JP | 2000-572198 | •• | 19990921 |
| | | | GB | 1998-20770 | А | 19980925 |
| | | | GB | 1998-26938 | Α | 19981209 |
| | | | GB | 1999-5969 | | 19990317 |
| • | | | WO | 1999-GB3144 | W | 19990921 |
| NO 2001001492 | A | 20010523 | NO | 2001-1492 | | 20010323 |
| | | | GB | 1998-20770 | Α | 19980925 |
| | | | GB | 1998-26938 | Α | 19981209 |
| | | | GB | 1999-5969 | Α | 19990317 |
| | | | WO | 1999-GB3144 | W | 19990921 |
| US 6455520 | B1 | 20020924 | US | 2001-787882 | | 20010323 |
| | | | GB | 1998-20770 | Α | 19980925 |
| | | | GB | 1998-26938 | Α | 19981209 |
| | | | GB | 1999-5969 | Α | 19990317 |
| | | | WO | 1999-GB3144 | W | 19990921 |
| | | | | | | |

OS MARPAT 132:265091

IT 263269-52-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-(benzamidophenyl)pyridinecarboxamides and analogs as cytokine prodn. inhibitors)

RN 263269-52-9 CAPLUS

CN 4-Pyridinecarboxamide, 2-(cyclobutylamino)-N-[4-methyl-3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]phenyl]- (9CI) (CA INDEX NAME)

GΙ

AB R4Z4ZCONHZ1NHCOZ2R2 [I; R2 = Z3R3; R3 = (un)substituted heteroaryl; R4 = (di)(alkyl)amino(alkyl), heterocyclyl(alkyl), heteroaryl(alkyl), etc.; Z = (un)substituted phenylene; Z1= 2-halo- or -alkyl-1,5-phenylene; Z2 = bond or (CH2)1-4; Z3 = bond, O, NH, alkyleneoxy, alkyleneamino, etc.; Z4 = bond, alkylene(oxy), alkyleneamino, etc.] were prepd. as p38 kinase inhibitors. Thus, 3-(ClCH2)C6H4COCl was amidated by 2-methyl-5-

nitroaniline and the product aminated by 1-methylpiperazine to give, after redn. and pyridine-3-carbonyl chloride amidation, title compd. II. Data for biol. activity of I were given.

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 5 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS
L4
     1999:784082 CAPLUS
AN
DN
     132:22963
     Preparation of N-(pyrazolylphenyl)alkanamides and analogs as IL-2
TI
```

production inhibitors

Betageri, Rajashekhar; Cywin, Charles L.; Hargrave, Karl; Hoermmann, Mary IN Ann; Kirrane, Thomas M.; Parks, Thomas M.; Patel, Usha R.; Proudfoot, John . R.; Sharma, Rajiv; Sun, Sanxing; Wang, Xiao-Jun

Boehringer Ingelheim Pharmaceuticals, Inc., USA PA

SO PCT Int. Appl., 130 pp. CODEN: PIXXD2

DT Patent English . LA

FAN.CNT 1 PATENT NO.

| | PATENT NO. | | APPLICATION NO. DATE |
|----|---------------------------------------|--------------------|---------------------------------------|
| | | | |
| PΙ | WO 9962885 | A1 19991209 | WO 1999-US12295 19990603 |
| | W: AL, AM, | AT, AU, AZ, BA, BB | , BG, BR, BY, CA, CH, CN, CU, CZ, DE, |
| | | | , GM, HR, HU, ID, IL, IS, JP, KE, KG, |
| | | | , LU, LV, MD, MG, MK, MN, MW, MX, NO, |
| | · · · · · · · · · · · · · · · · · · · | | , SG, SI, SK, SL, TJ, TM, TR, TT, UA, |
| | | VN, YU, ZW | ,,,,,,,,, |
| | | | US 1998-88154P P 19980605 |
| | CA 2332957 | AA 19991209 | CA 1999-2332957 19990603 |
| | | | US 1998-88154P P 19980605 |
| | | | WO 1999-US12295W 19990603 |
| | AU 9942299 | A1 19991220 | AU 1999-42299 19990603 |
| | | | US 1998-88154P P 19980605 |
| | | | WO 1999-US12295W 19990603 |
| | JP 2002516909 | T2 20020611 | JP 2000-552097 19990603 |
| • | | | US 1998-88154P P 19980605 |
| | | | WO 1999-US12295W 19990603 |
| | US 6506747 | B1 20030114 | US 1999-324933 19990603 |
| | | | US 1998-88154P P 19980605 |
| | | | |

OS MARPAT 132:22963

ΙT 251656-67-4P 251656-70-9P 251656-71-0P 251656-99-2P 251657-01-9P 251657-03-1P 251657-04-2P 251657-05-3P 251657-34-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)

RN 251656-67-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

RN 251656-70-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

RN 251656-71-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[2-(4-morpholinyl)ethyl]amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

RN 251656-99-2 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(2-hydroxyethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 251657-01-9 CAPLUS

CN 4-Pyridinecarboxamide, 2-[(5-hydroxypentyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

NH-
$$CH_2$$
) 5-OH

RN 251657-03-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[(2-hydroxyethyl)amino]- (9CI) (CA INDEX NAME)

RN 251657-04-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[(5-hydroxypentyl)amino]- (9CI) (CA INDEX NAME)

RN 251657-05-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

RN 251657-34-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]phenyl]-6-[(3-hydroxypropyl)amino]- (9CI) (CA INDEX NAME)

. GI

$$R^3$$
 $R-N$
 R^2
 R^1
 R^1

AB Title compds. [I; R = R4Z1Z; R1,R3 = halo, CF3, alkyl, alkoxy, etc.; R2 = H, halo, Me; R4 = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z = 1,4-phenylene; Z1 = CONH, CO2NH, NH, etc.] were prepd. Thus, I [R = 4-(R5HN)C6H4, R1 = R3 = CF3, R2 = H](II; R5 = H) was amidated by cyclohexanecarboxylic acid to give II (R5 = cyclohexylcarbonyl). Data for biol. activity of I were given.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS
- AN 1998:324820 CAPLUS
- DN 129:16148
- TI Preparation of tricyclic benzodiazepines as vasopressin antagonists
- IN Albright, Jay Donald; Venkatesan, Aranapakam M.; Dusza, John P.; Sum, Fuk-wah
- PA American Cyanamid Co., USA
- SO U.S., 119 pp., Cont.-in-part of U.S. 5,536,718. CODEN: USXXAM
- DT Patent

| LA FAN. | | glish | | | | | | | | | | | | | | | | |
|------------|------|----------------|------|-----|------------|-----|--------------|--------------|-----|-----|--------------|----------|--------------|------|---------------|------|-----|-----|
| FAIN. | PA | rent : | NO. | | KI | ND | DATE | | | A | PPLI | CATI | ON N | Ο. | DATE | | | |
| PI | US | 5753 | 648 | | | | 1998 | 0519 | | | | | | | 1996 1995 | | | |
| | | 5536 | | | | | | | | U | S 19 | 95-3 | 7313 | 2 | 1995 | 0117 | | |
| | | 2258 | | | A | | 1997 | | | U | S 19 | 96-6 | 7215 | 0 A | 1997 1996 | 0627 | | |
| | WO | 9749 W: | | | | | 1997 BG, | | | | | | | | | | TT. | τς |
| | | ,,, | JP, | KP, | KR, | LC, | LK, | LR, | LT, | LV, | MG, | MK, | MN, | MX, | NO, | NZ, | PL, | RO, |
| | | | | | SI, RU, | | SL, TM | TR, | TT, | UA, | UZ, | VN, | YU, | ZW, | AM, | AZ, | BY, | KG, |
| | | RW: | GH, | KE, | LS, | MW, | SD, | | | | | | | | | | | |
| | | | | | | | LU, SN, | | | PT, | SE, | BF, | BJ, | CF, | CG, | C1, | CM, | GA, |
| | 7.11 | 9734 | | | | | | | | | | | | | 1996 1997 | | | |
| | | 7319 | | | B | 2 | 1998 2001 | 0405 | | А | 0 19 | J1-3 | 4063 | | 1337 | 0620 | | |
| | | | | | | | | | | _ | | | | | 1996 1997 | | | |
| | ĒΡ | 9158 | | | | | | 0519 | | E | P 19 | 97-9 | 3016 | 7 | 1997 | 0620 | | |
| | | R: | | | CH, LV, | | DK, RO | ES, | FR, | GB, | GR, | IT, | LI, | LU, | NL, | SE, | PT, | IE, |
| | | | • | · | · | , | | | | | | | | | 1996 1997 | | | |
| | BR | 9710 | 087 | | А | | 1999 | 0810 | | | | | | | 1997 | | | |
| | | | | | | | | | | | | | | | 1996 1997 | | | |
| | CN | 1231 | 666 | | А | | 1999 | 1013 | | C | N 19 | 97-1 | 9741 | 3 | 1997 | 0620 | | |
| | JР | 2000 | 5101 | 54 | T | 2 | 2000 | 0808 | | | | | | | 1996 1997 | | | |
| | | | | | | | | | | U | S 19 | 96-6 | 7215 | 0 A | 1996 | 0627 | | |
| | NZ | 3326 | 05 | | А | • | 2000 | 0929 | | | | | | | 1997 1997 | | | |
| | КD | 2000 | 0222 | 07 | 7 | | 2000 | 0425 | | | | | | | 1996 1998 | | | |
| | | | | | | | 2000 | 0423 | | | | | | | 1996 | | | |
| | | FAMIL 96:46 | | | ATIO | N : | | | | | | | | | | | | |
| | PA' | TENT | NO. | | KI | ND | DATE | | | A | PPLI | CATI | ON N | Ο. | DATE | | | |
| PI | US | 5536 | 718 | | A | | 1996 | 0716 | | U | s 19 | 95-3 | 7313 | 2 | 1995 | 0117 | | |
| | US | 5610 | 156 | | A | | 1997 | 0311 | | | | | 5821 7313 | | 1995 1995 | | | |
| | US | 5612 | 334 | | A | | 1997 | 0318 | | U | S 19 | 95-4 | 6034 | 6 | 1995 | 0602 | | |
| | ZA | 9600 | 297 | | А | | 1997 | 0715 | | | S 19 A 19 | | | 2 A3 | 31995 1996 | | | |
| | CA | 2210 | 621 | | A | 7. | 1996 | 07 25 | | | | | | | 1995 | | | |
| | CA | 2210 | 631 | | A | A | 1990 | 0725 | | U | S 19 | 95-3 | | 2 A | 1996 1995 | | | |
| | WO | 9622 W: | | ДΜ | AU. | | 1996 BG, | | | | | | S107 | | 1996 HU: | | σŢ | KG |
| | | *** | ΚP, | KR, | LK, | LR, | LT, | LU, | LV, | MD, | MG, | MK, | MN, | MX, | NO, | NZ, | PL, | |
| | | RW: | | | | | TT, | | | | | | | | | | | IE. |
| | | | | | | | PT, | | | | | | | | | | | |

| | | NE, SN | , TD, TG | | | • | | | | | | | | |
|-----------|-----------------------------------|--|---|---|-------------------------------------|---|---|---|---|--|---|---|--|---------------------|
| | | | | | | US | 1995 | 5-373 | 3132 | Α | 1995 | 0117 | | |
| | AU 9647 | 7698 | A1 | 19960807 | | AU | 1996 | 6-476 | 598 | | 1996 | 0116 | | |
| | AU 7079 | 982 | B2 | 19990722 | • | | | | • | | | | | |
| | | | | | | US | 1995 | 5-373 | 3132 | Α | 1995 | 0117 | | |
| | | | | | | WO | 1996 | 5-US1 | 1076 | W | 1996 | 0116 | | |
| | EP 8044 | 138 | A1 | 19971105 | | EP | 1996 | 5-903 | 3698 | | 1996 | 0116 | | |
| | | | | , DK, ES, | | | | | | | | | | IE, |
| | | SI, LT | | , | • | , | • | • | • | · | • | • | • | • |
| | | | | | | US | 1995 | 5-373 | 3132 | Α | 1995 | 0117 | | |
| | | | | | | | 1996 | | | | | | | |
| | BR 9607 | 7182 | Α | 19971111 | | | 1996 | | | | | | | |
| | | | | | | | 1995 | | | | | | | |
| | | | | | | | 1996 | | | | | | | |
| | CN 1198 | 3746 | Α | 19981111 | | | 1996 | | | | | | | |
| | CN 1065 | 5244 | В | 20010502 | | - | | | | | | | | |
| | | | _ | | | US | 1995 | 5-373 | 3132 | Α | 1995 | 0117 | | |
| | JP 1150 | 0106 | Т2 | 19990106 | | JP | 1996 | | | | | | | |
| | | | | | | US | 1995 | | | | | | | |
| | | | | | | | 1996 | | | | | | | |
| | 11, 1167 | 775 | Δ1 | 19990817 | | | | | | | | | | |
| | 110 110, | | | | | TIC | 1995 | | | | | | | |
| | TW 4037 | 752 | В | 20000901 | | TW. | 1996 | | | | | | | |
| | | | _ | 20000501 | | US | 1995 | | | | | | | |
| | US 5700 | 796 | Δ | 19971223 | | | | | | | | | | |
| | 05 5.00 | ,,,, | •• | 177,1223 | | | 1995 | | | | | | | |
| | US 5753 | 1648 | - A | 19980519 | | US | 1996 | 5-672 | 150 | n. | 1996 | 0627 | | |
| | 00 3,33 | ,010 | •• | 1000010 | | 115 | 1995 | 5-373 | 1130 | Δ2 | 1005 | 0027 | | |
| FAN | 1998:82 | 260 | | | | 05 | 1)) | J - J / J | 1122 | A | 1))) | 0117 | | |
| | PATENT | NO. | KIND | DATE | | ΔD | PLICA | ארד הא | I NO | | איד ערו | | | |
| | | · | | | | | | | | | | | | |
| PΙ | US 5700 | 796 | Δ | 19971223 | | | | | | | | | | |
| • • | 05 3.00 | | •• | 100,1225 | | 115 | 1995 | 5-373 | 1112 | Δ 2 | 1995 | 0027 | | |
| | US 5536 | 718 | Δ | 19960716 | | נוכ | 1995 | 5-373 5-373 | 1132 | AZ | 1005 | 0117 | | |
| | WO 9749 | 708 | Δ1 | 19971231 | | พด | 1997 | 7_1191 | 0751 | = | 1997 | 0520 | | |
| | W: | | | , BG, BR, | | | | | | | | | TT. | TC |
| | ,, , | | | LK, LR, | | | | | | | | | | |
| | | | | | | 1.1/ 1 | IVI(-i V | | | | | | | κo, |
| | | RU SG | ST SK | SI, TR | тт, тт, | т∧' 1 | MG, M UZ V | 7NT V | יייייייייייייייייייייייייייייייייייייי | 711, 711 | MΔ | NZ;, | PV, | KC |
| | | RU, SG, | SI, SK | , SL, TR, | TT, | UA, I | MG, M UZ, V | л, у Л, у | TU, 2 | ZW, | AM, | AZ, | BY, | KG, |
| | RW. | RU, SG, KZ, MD, | SI, SK, RU, TJ, | , SL, TR, , TM | TT, | UA, 1 | UZ, V | ЛΝ, Υ | ປ, : | ZW, | AM, | AZ, | BY, | • |
| | RW: | RU, SG, KZ, MD, GH, KE, | SI, SK, RU, TJ, LS, MW, | , SL, TR, , TM , SD, SZ, | TT, | UA, I | UZ, V AT, B | ЛN, Y ВЕ, С | ти, г тн, і | ZW, DE, | AM, DK, | AZ, ES, | BY, | FR, |
| | RW: | RU, SG, KZ, MD, GH, KE, GB, GR, | SI, SK, RU, TJ, LS, MW, IE, IT, | , SL, TR, , TM , SD, SZ, , LU, MC, | TT, UG, NL, | UA, I | UZ, V AT, B | ЛN, Y ВЕ, С | ти, г тн, і | ZW, DE, | AM, DK, | AZ, ES, | BY, | FR, |
| | RW∙: | RU, SG, KZ, MD, GH, KE, GB, GR, | SI, SK, RU, TJ, LS, MW, IE, IT, | , SL, TR, , TM , SD, SZ, | TT, UG, NL, | UA, I | UZ, V AT, E SE, E | <i>J</i> N, Y BE, C BF, E | ZU, Z ZH, I BJ, (| ZW, DE, CF, | AM, DK, CG, | AZ, ES, CI, | BY, | FR, |
| | | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, | TT, UG, NL, | UA, US | UZ, V AT, B SE, B | <i>J</i> N, Y BE, C BF, E 5-671 | TU, 1 CH, I BJ, 0 | ZW, DE, CF, A | AM, DK, CG, | AZ, ES, CI, | BY, | FR, |
| | | RU, SG, KZ, MD, GH, KE, GB, GR, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, | , SL, TR, , TM , SD, SZ, , LU, MC, | TT, UG, NL, | UA, I | UZ, V AT, B SE, B 1996 1997 | JN, Y BE, C BF, E 5-671 7-364 | TU, Z TH, I BJ, (1442 14 | ZW, DE, CF, | AM, DK, CG, 1996 | AZ, ES, CI, 0627 | BY, | FR, |
| | | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, | TT, UG, NL, | UA, I ZW, A PT, S US AU US | UZ, V AT, E SE, E 1996 1997 1996 | 7N, Y BE, C BF, E 5-671 7-364 5-671 | CH, I BJ, (.442 .14 | ZW, DE, CF, A | AM, DK, CG, 1996 1997 | AZ, ES, CI, 0627 0620 0627 | BY, | FR, |
| FAN | AU 9736 | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, | TT, UG, NL, | UA, I ZW, A PT, S US AU US | UZ, V AT, B SE, B 1996 1997 | 7N, Y BE, C BF, E 5-671 7-364 5-671 | CH, I BJ, (.442 .14 | ZW, DE, CF, A | AM, DK, CG, 1996 1997 | AZ, ES, CI, 0627 0620 0627 | BY, | FR, |
| FAN | AU 9736 | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, | TT, UG, NL, | ZW, Z PT, S US AU US WO | UZ, V AT, E SE, B 1996 1997 | JN, Y BE, C BF, E 5-671 7-364 5-671 7-US1 | TU, Z TH, I 3J, (442 14 .442 .075 | ZW, DE, CF, A A | AM, CG, 1996 1997 1996 | AZ, ES, CI, 0627 0620 0627 | BY, | FR, |
| FAN | AU 9736 1998:42 PATENT | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, | TT, UG, NL, | ZW, Z PT, S US AU US WO | UZ, V AT, E SE, E 1996 1997 1996 | JN, Y BE, C BF, E 5-671 7-364 5-671 7-US1 | TU, Z TH, I 3J, (442 14 .442 .075 | ZW, DE, CF, A A | AM, DK, CG, 1996 1997 | AZ, ES, CI, 0627 0620 0627 | BY, | FR, |
| | AU 9736 1998:42 PATENT | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, 414 | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, 19980114 | TT, UG, NL, | UA, I ZW, Z PT, S US AU US WO | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA | JN, Y BE, C BF, E 5-671 7-364 7-US1 ATION | TU, 2 TH, I 3J, (.442 .14 .442 .075! | ZW, DE, CF, A A SW | AM, DK, CG, 1996 1997 1996 1997 | AZ, ES, CI, 0627 0620 0627 0620 | BY, | FR, |
| FAN PI | AU 9736 1998:42 PATENT WO 9749 | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, 6414 4402 NO. | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 KIND A1 | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, 19980114 DATE | TT, UG, NL, TG | UA, I ZW, A PT, S AU US WO APS WO | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 | JN, Y BE, C BF, E 5-671 7-364 5-671 7-US1 ATION 7-US1 | TU, 2 3J, (442 14 .442 .0755 I NO | ZW, DE, CF, A A SW | AM, DK, CG, 1996 1997 1996 1997 | AZ, ES, CI, 0627 0620 0627 0620 | BY, FI, CM, | FR, GA, |
| | AU 9736 1998:42 PATENT | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, 414 2402 NO. 2707 AL, AU, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 KIND A1 BA, BB, | , SL, TR, , TM , SD, SZ, , LU, MC, , SN, TD, 19980114 DATE 19971231 , BG, BR, | TT, UG, NL, TG | UA, I ZW, A PT, S AU US WO AP: WO CN, G | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 CU, C | 7N, Y 3E, C 3F, E 5-671 7-364 5-671 7-US1 ATION 7-US1 CZ, E | TU, 2 SJ, 0 .442 .14 .442 .075! I NO .0736 | ZW, DE, CF, A A SW | AM, DK, CG, 1996 1997 1996 1997 DATE 1997 GH, | AZ, ES, CI, 0627 0620 0627 0620 HU, | BY, FI, CM, | FR, GA, |
| | AU 9736 1998:42 PATENT WO 9749 | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, 414 402 NO. 2707 AL, AU, JP, KP, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 KIND A1 BA, BB, KR, LC, | DATE 19971231 BG, BR, LK, LR, | TT, UG, NL, TG CA, LT, | UA, I ZW, Z PT, S AU US WO AP: WO CN, G LV, I | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 CU, C | 7N, Y 3E, C 3F, E 5-671 7-364 5-671 7-US1 ATION 7-US1 CZ, E | TU, 2 SJ, (1 442 14 442 .075 I NO .073 EE, (1 IN, N | ZW, DE, CF, A A A SGE, VX, | AM, DK, CG, 1996 1997 1996 1997 DATE 1997 GH, NO, | AZ, ES, CI, 0627 0620 0627 0620 HU, NZ, | BY, FI, CM, | FR, GA, |
| | AU 9736 1998:42 PATENT WO 9749 | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, 6414 2402 NO. 7707 AL, AU, JP, KP, RU, SG, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 KIND A1 BA, BB, KR, LC, SI, SK, | DATE 19971231 BG, BR, LK, LR, SL, TR, | TT, UG, NL, TG CA, LT, | UA, I ZW, Z PT, S AU US WO AP: WO CN, G LV, I | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 CU, C | 7N, Y 3E, C 3F, E 5-671 7-364 5-671 7-US1 ATION 7-US1 CZ, E | TU, 2 SJ, (1 442 14 442 .075 I NO .073 EE, (1 IN, N | ZW, DE, CF, A A A SGE, VX, | AM, DK, CG, 1996 1997 1996 1997 DATE 1997 GH, NO, | AZ, ES, CI, 0627 0620 0627 0620 HU, NZ, | BY, FI, CM, | FR, GA, |
| | AU 9736 1998:42 PATENT WO 9749 W: | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, 6414 2402 NO. 7707 AL, AU, JP, KP, RU, SG, KZ, MD, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 KIND A1 BA, BB, KR, LC, SI, SK, RU, TJ, | DATE 19971231 BG, BR, LK, LR, SL, TR, TM | TT, UG, NL, TG CA, LT, TT, | UA, I ZW, Z PT, S AU US WO AP: WO CN, G LV, I UA, I | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 CU, C MG, M UZ, V | 7N, Y 3E, C 3F, E 5-671 7-364 5-671 7-US1 ATION 7-US1 CZ, E 4K, M 7N, Y | TU, 2 CH, I BJ, (442 14 442 075! I NO .0736 EE, (IN, N | ZW, DE, CF, A A SW . SGE, AX, ZW, | AM, CG, 1996 1997 1996 1997 DATE 1997 GH, NO, AM, | AZ, ES, CI, 0627 0620 0627 0620 HU, NZ, AZ, | BY, FI, CM, | FR, GA, |
| | AU 9736 1998:42 PATENT WO 9749 W: | RU, SG, KZ, MD, GH, KE, GB, GR, GN, ML, 6414 402 NO. 707 AL, AU, JP, KP, RU, SG, KZ, MD, GH, KE, | SI, SK, RU, TJ, LS, MW, IE, IT, MR, NE, A1 KIND A1 BA, BB, KR, LC, SI, SK, RU, TJ, LS, MW, | DATE 19971231 BG, BR, LK, LR, SD, SZ, LU, MC, SN, TD, 19980114 | TT, UG, NL, TG CA, LT, TT, UG, | UA, IVA, IVA, IVA, IVA, IVA, IVA, IVA, IV | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 CU, C MG, M UZ, V | 7N, Y 3E, C 3F, E 5-671 7-364 5-671 7-US1 ATION 7-US1 CZ, E 4K, M 7N, Y | TU, 2 1442 1442 0755 1 NO 0736 CE, (1) TU, 2 | ZW, DE, CF, A A SW . GGE, AX, ZW, DE, | AM, DK, CG, 1996 1997 DATE 1997 GH, NO, AM, DK, | AZ, ES, CI, 0627 0620 0627 0620 HU, NZ, AZ, | BY, FI, CM, IL, PL, BY, | FR, GA, IS, RO, KG, |
| | AU 9736 1998:42 PATENT WO 9749 W: | RU, SG, KZ, MD, GH, KE, GB, GR, ML, S414 2402 NO. 7707 AL, AU, JP, KP, RU, SG, KZ, MD, GH, KE, GB, GR, | SI, SK, RU, TJ, LS, MW, IE, IT, SK, RU, TJ, LS, MW, IE, IT, | DATE 19971231 BG, BR, LK, LR, SD, SZ, LU, MC, 19980114 | TT, UG, NL, TG CA, LT, TT, UG, NL, | UA, IVA, IVA, IVA, IVA, IVA, IVA, IVA, IV | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 CU, C MG, M UZ, V | 7N, Y 3E, C 3F, E 5-671 7-364 5-671 7-US1 ATION 7-US1 CZ, E 4K, M 7N, Y | TU, 2 CH, I BJ, (1) 442 1442 0755 I NO 0736 CE, (1) TU, 2 | ZW, DE, CF, A A SW . GGE, AX, ZW, DE, | AM, DK, CG, 1996 1997 DATE 1997 GH, NO, AM, DK, | AZ, ES, CI, 0627 0620 0627 0620 HU, NZ, AZ, | BY, FI, CM, IL, PL, BY, | FR, GA, IS, RO, KG, |
| | AU 9736 1998:42 PATENT WO 9749 W: | RU, SG, KZ, MD, GH, KE, GB, GR, ML, S414 2402 NO. 7707 AL, AU, JP, KP, RU, SG, KZ, MD, GH, KE, GB, GR, | SI, SK, RU, TJ, LS, MW, IE, IT, SK, RU, TJ, LS, MW, IE, IT, | DATE 19971231 BG, BR, LK, LR, SD, SZ, LU, MC, SN, TD, 19980114 | TT, UG, NL, TG CA, LT, TT, UG, NL, | UA, I ZW, Z PT, S AU US WO AP: WO CN, G LV, I UA, I | UZ, V AT, E SE, E 1996 1997 1996 1997 PLICA 1997 CU, C MG, M UZ, V | ON, Y BE, C 6-671 7-364 7-US1 ATION 7-US1 CZ, E MK, M ON, Y BE, C BF, B | TU, 2 CH, I BJ, 0 442 1442 0755 I NO 0736 CE, 0 NN, N TU, 2 CH, I BJ, 0 | ZW, CF, A A SW GGE, AZW, DE, | AM, CG, 1996 1997 1996 1997 DATE 1997 GH, NO, AM, CG, | AZ, ES, CI, 0627 0620 0627 0620 HU, NZ, AZ, CI, | BY, FI, CM, IL, PL, BY, | FR, GA, IS, RO, KG, |

| 10046 | 526 | . 2 | | Page | 124 | | | | | | | | | | | |
|-------|-----|--------|---------|------|---------|-----------|-----|-------|------|------|------|------|-------|------|------|-------|
| | US | 57536 | 48 | | A | 19980519 | | US | 199 | 6-67 | 7215 | 0 | 1996 | 0627 | | |
| | | | | | | | | US | 199 | 5-37 | 7313 | 2 A2 | 21995 | 0117 | | |
| | ΑU | 97340 | 63 | | A1 | 19980114 | | AU | 199 | 7-34 | 1063 | | 1997 | 0620 | | |
| | ΑU | 73192 | 5 | | B2 | 20010405 | | | | | | | | | | |
| | | | | | | | | US | 199 | 6-67 | 7215 | 0 A | 1996 | 0627 | | • |
| | | | | | | | | WO | 199 | 7-US | 5107 | 36W | 1997 | 0620 | | |
| | ΕP | 91587 | 6 | | A1 | 19990519 | | EP | 199 | 7-93 | 3016 | 7 | 1997 | 0620 | | |
| | | R: | AT, | BE, | CH, DE | , DK, ES, | FR, | GB, G | GR, | IT, | LI, | LU | , NL, | SE, | PT, | ΙE, |
| | | | | | LV, FI | | | | · | - | | | | | | |
| | | | | - | | | | US | 199 | 6-67 | 7215 | 0 A | 1996 | 0627 | | |
| | | | | | | | | WO | 199 | 7-US | 3107 | 36W | 1997 | 0620 | | |
| | BR | 97100 | 87 | | Α | 19990810 | | BR | 199 | 7-10 | 0087 | | 1997 | 0620 | | |
| | | | | | | | | US | 199 | 6-67 | 7215 | 0 A | 1996 | 0627 | | |
| | | | | | | | | WO | 199 | 7-US | 3107 | 36W | 1997 | 0620 | • | |
| | JΡ | 20005 | 1015 | 54 | T2 | 20000808 | • | JР | 199 | 8-50 | 0337 | 9 | 1997 | 0620 | | |
| | | | | | | | | US | 199 | 6-67 | 7215 | 0 A | 1996 | 0627 | | |
| | | | | | | | | WO | 199 | 7-US | 5107 | 36W | 1997 | 0620 | | |
| os | MAF | RPAT 1 | 29:1 | 6148 | | | | | | | | | | | | |
| IT | 180 | 416-7 | 0 - 0 E | 180 | 416-71 | -1P | | | | | | | | | | |
| | RL | BAC | (Bic | logi | cal aci | tivity or | eff | ector | . ex | cept | : ad | vers | se): | BSU | (Bio | logic |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tricyclic benzodiazepines as vasopressin antagonists)

RN 180416-70-0 CAPLUS

3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

CN

RN180416-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5Hpyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

NH-
$$(CH_2)_3$$
-NMe₂

C=0

NH

NH

NH

GΙ

Title compds. [I; D,E,F = N or (un)substituted CH; R1R2 = atoms to complete an(un)substituted (hetero)arom. ring; Y = bond, CH2, CH2CH2, CO, alkylidene; Z = (CH2)mNR3 or NR3(CH2)m; R3 = COZ1R6; R6 = acylamino, etc.; Z1 = (un)substituted 1,4-phenylene or -3,6-pyridinediyl; m = 1 or 2] were prepd. Thus, 1-(2-nitrobenzyl)pyrrole-2-carboxaldehyde (prepn. given) was reductively cyclized and the product N-acylated by 2-PhC6H4CONHC6H4(OMe)(CO2H)-3,4 (prepn. given) to give, after condensation with HCHO/CH2(NMe2)2, title compd. II. Data for biol. activity of I were given.

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS
- AN 1998:268489 CAPLUS
- DN 128:321568
- TI Anthranilic acid derivatives as multi drug resistance modulators
- IN Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael John; Brumwell, Julie Elizabeth; Hunjan, Sukhjit; Folkes, Adrian John; Sanderson, Jason Terry; Williams, Susannah; Maximen, Levi Michael; et al.
- PA Xenova Ltd., UK; Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael

John; Brumwell, Julie Elizabeth; Hunjan, Sukhjit; Folkes, Adrian John; Sanderson, Jason Terry; Williams, Susannah; Maximen, Levi Michael PCT Int. Appl., 203 pp. SO CODEN: PIXXD2 DT Patent English LA FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE -----A1 WO 9817648 19980430 WO 1997-GB2885 PΙ 19971017 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG WO 1996-GB2552 A 19961018 GB 1997-17576 A 19970819 AU 9746339 A1 19980515 AU 1997-46339 19971017 AU 741922 B2 20011213 WO 1996-GB2552 A 19961018 GB 1997-17576 A 19970819 WO 1997-GB2885 W 19971017 ZA 1997-9329 ZA 9709329 Α 19990419 19971017 WO 1996-GB2552 A 19961018 EP 934276 19990811 Α1 EP 1997-945030 19971017 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI WO 1996-GB2552 W 19961018 GB 1997-17576 A 19970819 WO 1997-GB2885 W 19971017 BR 9711935 Α 19990824 BR 1997-11935 19971017 WO 1996-GB2552 A 19961018 GB 1997-17576 A 19970819 WO 1997-GB2885 W 19971017 GB 2334521 Α1 GB 1999-8193 19990825 19971017 GB 2334521 В2 20001004 WO 1996-GB2552 A 19961018 GB 1997-17576 A 19970819 WO 1997-GB2885 W 19971017 CN 1241181 Α 20000112 CN 1997-180708 19971017 WO 1997-GB2885 W 19971017 JP 2001502683 20010227 T2 JP 1998-519108 19971017 WO 1996-GB2552 W 19961018 GB 1997-17576 A 19970819 WO 1997-GB2885 W 19971017 RU 2195454 C2 20021227 RU 1999-109990 WO 1996-GB2552 A 19961018 GB 1997-17576 A 19970819 WO 1997-GB2885 W 19971017 BG 103327 Α 20001130 BG 1999-103327 19990413 WO 1996-GB2552 A 19961018 GB 1997-17576 A 19970819 WO 1997-GB2885 W 19971017 NO 9901836 Α 19990617 NO 1999-1836 19990416 WO 1996-GB2552 A 19961018

| | | | GB 1997-17576 A 19970819 |
|---------------|----|----------|---------------------------|
| | | | WO 1997-GB2885 W 19971017 |
| KR 2000049278 | Α | 20000725 | KR 1999-703389 19990417 |
| | | | WO 1996-GB2552 A 19961018 |
| | | | GB 1997-17576 A 19970819 |
| US 6218393 | B1 | 20010417 | US 1999-284642 19990609 |
| | | | GB 1997-17576 A 19970819 |
| | | | WO 1997-GB2885 W 19971017 |
| HK 1019330 . | Al | 20010112 | HK 1999-103773 19990901 |
| | | | WO 1996-GB2552 W 19961018 |
| | | | GB 1997-17576 A 19970819 |
| | | | WO 1997-GB2885 W 19971017 |

OS MARPAT 128:321568

IT 206872-39-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anthranilic acid derivs. as multi-drug resistance modulators)

RN 206872-39-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} N & O \\ \hline & C \\ N & C \\ \hline & NH \\ \hline & C \\ \hline & CH_2-CH_2-N \\ \hline & OMe \\ \hline & OMe \\ \hline \end{array}$$

GI

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- Anthranilic acid derivs. I [R, R1, R2 = H, alkyl, OH, alkoxy, halo, NO2, amino; or R1R2 = OCH2O or OCH2CH2O; R3 = H, alkyl; R4 = alkyl, or CH2 or CH2CH2 bridged to either Ph ring; R5 = H, OH, alkyl; X = bond, O, S, S(CH2)p, O(CH2)p; p = 1-6; R6 = H, alkyl, alkoxy; q = 0 or 1; Ar = (un)satd. carbo- or heterocyclic; R7, R8 = H, (un)substituted alkyl, alkoxy, OH, halo, Ph, NHOH, NO2, amino, SH, alkylthio; or R7R8 = CH:CHCH:CH or OCH2O; n = 0, 1; m = 0-6] and their pharmaceutically acceptable salts are disclosed. The compds. are inhibitors of P-glycoprotein, and may thus be used, inter alia, as modulators of multidrug resistance in the treatment of multidrug-resistant cancers, for example, to potentiate the cytotoxicity of a cancer drug. For instance, amidation of 3-quinolinecarboxylic acid with the corresponding aminothiophene deriv. via the acid chloride gave title compd. II in 44% yield. In a test for potentiation of doxorubicin toxicity to AR 1.0

cells, II had a potentiation index of 142 at 30 nM. RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS L4 AN 1998:42402 CAPLUS DN 128:114970 Preparation of tricyclic benzazepine as vasopressin antagonists ΤI IN Albright, Jay Donald; Venkatesan, Aranapakam Mudumbai; Dusza, John Paul; Sum, Fuk-wah PA American Cyanamid Co., USA SO PCT Int. Appl., 411 pp. CODEN: PIXXD2 DT Patent English LΑ FAN.CNT 4 PATENT NO. KIND DATE APPLICATION NO. **A**1 PΙ WO 9749707 19971231 WO 1997-US10736 19970620 W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG US 1996-672150 A 19960627 US 5753648 19980519 Α US 1996-672150 19960627 US 1995-373132 A219950117 AU 9734063 Α1 19980114 AU 1997-34063 19970620 AU 731925 B2 20010405 US 1996-672150 A 19960627 WO 1997-US10736W 19970620 EP 915876 Α1 19990519 EP 1997-930167 19970620 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO US 1996-672150 A 19960627 WO 1997-US10736W 19970620 BR 9710087 Α 19990810 BR 1997-10087 19970620 US 1996-672150 A 19960627 WO 1997-US10736W 19970620 JP 2000510154 T2 20000808 JP 1998-503379 19970620 US 1996-672150 A 19960627 WO 1997-US10736W 19970620 PATENT FAMILY INFORMATION: ENN 1006.460027

| FAN | 1996:469927 | | | |
|-----|-------------|------|----------|---------------------------|
| | PATENT NO. | KIND | DATE | APPLICATION NO. DATE |
| | | | | |
| ΡI | US 5536718 | Α | 19960716 | US 1995-373132 19950117 |
| | US 5610156 | A | 19970311 | US 1995-458210 19950602 |
| | | | | US 1995-373132 A319950117 |
| | US 5612334 | . A | 19970318 | US 1995-460346 19950602 |
| | | | | US 1995-373132 A319950117 |
| | ZA 9600297 | Α | 19970715 | ZA 1996-297 19960115 |
| | | | • | US 1995-373132 A 19950117 |
| | CA 2210631 | AA | 19960725 | CA 1996-2210631 19960116 |
| | | | | US 1995-373132 A 19950117 |
| | WO 9622293 | A1 | 19960725 | WO 1996-US1076 19960116 |
| | | | | |

| 1004 | 6526 .2 | Page 129 | |
|------|------------------------------|--|---|
| | KP, SG, RW: KE, IT, | AM, AU, BB, BG, BR, CA, CN, CZ, KR, LK, LR, LT, LU, LV, MD, MG, SI, SK, TR, TT, UA, UZ, VN, AZ, LS, MW, SD, SZ, UG, AT, BE, CH, LU, MC, NL, PT, SE, BF, BJ, CF, SN, TD, TG | MK, MN, MX, NO, NZ, PL, RO, BY, KG, KZ, RU, TJ, TM DE, DK, ES, FR, GB, GR, IE, CG, CI, CM, GA, GN, ML, MR, |
| | AU 9647698 AU 707982 | A1 19960807 AU 1 B2 19990722 US 1 | 995-373132 A 19950117 996-47698 19960116 995-373132 A 19950117 996-US1076 W 19960116 |
| | R: AT, | BE, CH, DE, DK, ES, FR, GB, GR LT, LV | 996-903698 19960116 , IT, LI, LU, NL, SE, PT, IE, 995-373132 A 19950117 |
| | BR 9607182 | WO 1 A 19971111 BR 1 US 1 | 996-US1076 W 19960116 996-7182 19960116 995-373132 A 19950117 996-US1076 W 19960116 |
| | CN 1198746 CN 1065244 | • | 996-192641 19960116 |
| | JP 11500106 | T2 19990106 JP 1 US 1 | 995-373132 A 19950117 996-522452 19960116 995-373132 A 19950117 |
| | IL 116775 | A1 19990817 IL 1 | 996-US1076 W 19960116 996-116775 19960116 995-373132 A 19950117 |
| | TW 403752 | | 996-85100461 19960116 995-373132 A 19950117 |
| | US 5700796 | A 19971223 US 1 US 1 | 996-671442 19960627 995-373132 A219950117 |
| | US 5753648 | | 996-672150 19960627 995-373132 A219950117 |
| FAN | 1998:8260 PATENT NO. | KIND DATE APPL | ICATION NO. DATE |
| PI | US 5700796 | A 19971223 US 1 | 996-671442 19960627 995-373132 A219950117 |
| | US 5536718 WO 9749708 | A 19960716 US 1 | 995-373132 19950117 997-US10755 19970620 |
| | JP, RU, | AU, BA, BB, BG, BR, CA, CN, CU KP, KR, LC, LK, LR, LT, LV, MG SG, SI, SK, SL, TR, TT, UA, UZ MD, RU, TJ, TM | K, MK, MN, MX, NO, NZ, PL, RO, |
| | GB, | KE, LS, MW, SD, SZ, UG, ZW, AT GR, IE, IT, LU, MC, NL, PT, SE ML, MR, NE, SN, TD, TG | |
| | AU 9736414 | US 1 A1 19980114 AU 1 US 1 | 996-671442 A 19960627 997-36414 19970620 996-671442 A 19960627 997-US10755W 19970620 |
| FAN | 1998:324820 PATENT NO. | | ICATION NO. DATE |
| ΡI | US 5753648 | A 19980519 US 1 | 996-672150 19960627 995-373132 A219950117 |
| | US 5536718 CA 2258885 | A 19960716 US 1 | 995-373132 |

```
US 1996-672150 A 19960627
                                         WO 1997-US10736 19970620
WO 9749707
                         19971231
                   Α1
        AL, AU, BA, BB, BG, BR, \cdot CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS,
        JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
        KZ, MD, RU, TJ, TM
    RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
        GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
        GN, ML, MR, NE, SN, TD, TG
                                         US 1996-672150 A 19960627
AU 9734063
                         19980114
                                         AU 1997-34063
                                                           19970620
                   A1
AU 731925
                         20010405
                   B2
                                         US 1996-672150 A 19960627
                                         WO 1997-US10736W 19970620
EP 915876
                                         EP 1997-930167
                   A1
                         19990519
                                                          19970620
       AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
        SI, LT, LV, FI, RO
                                         US 1996-672150 A 19960627
                                         WO 1997-US10736W 19970620
BR 9710087
                         19990810
                                         BR 1997-10087
                                                           19970620
                                         US 1996-672150 A 19960627
                                         WO 1997-US10736W 19970620
CN 1231666
                         19991013
                                         CN 1997-197413
                                                           19970620
                                         US 1996-672150 A 19960627
JP 2000510154
                         20000808
                   T2
                                         JP 1998-503379
                                                           19970620
                                         US 1996-672150 A 19960627
                                         WO 1997-US10736W 19970620
NZ 332605
                   Α
                         20000929
                                         NZ 1997-332605
                                                           19970620
                                         US 1996-672150 A 19960627
KR 2000022297
                                         KR 1998-710719
                         20000425
                                                           19981228
                                         US 1996-672150 A 19960627
MARPAT 128:114970
180416-70-0P 180416-71-1P
BIOL (Biological study); PREP (Preparation); USES (Uses)
```

IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

(prepn. of tricyclic benzazepines as vasopressin antagonists)

180416-70-0 CAPLUS RN

CN 3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1-

c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

OS

RN 180416-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

GI

AB The title compds. I [AB = CH2NR3, R3NCH2; R3 = (un)substituted arylcarbonyl; DEF ring = 5-member N-contg. (un)substituted heterocyclic ring; Y = .sigma.-bond, CH2; R = alkyl, NH2, halogen,etc; R1 = alkyl, OH, Cl, OMe, etc.], which exhibit antagonist activity at Vl and/or V2 receptors and exhibit in vivo vasopressin antagonist activity would be useful in treating diseases characterized by excess renal reabsorption of water (e.g., brain edema, cirrhosis, hyponatremia, brain edema, congestive heart failure, etc.), are prepd. Thus, 2-chloro-4-[(4'-trifluoromethyl)[1,1'-biphenyl-2-carbonyl]amino]benzoyl chloride was reacted with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4-]benzodiazepine, producing benzodiazepine II which demonstrated a rat kidney-derived V1 receptor IC50 of 41% at 1 .mu.M and 92% for the V2 receptor at 10 .mu.M.

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS

AN 1998:8260 CAPLUS

DN 128:88934

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay Donald; Venkatesan, Aranapakam M.; Dusza, John P.; Sum, Fuk-wah

PA American Cyanamid Co., USA

SO U.S., 64 pp., Cont.-in-part of U.S. 5,536,718.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|--------|-----------------|--------------------|-------------------|
| | | | | | |
| ΡI | US 5700796 | Α | 19971223 | US 1996-671442 | 19960627 |
| | | | | US 1995-373132 A | 219950117 |
| | US 5536718 | Α | 19960716 | US 1995-373132 | 19950117 |
| | WO 9749708 | A1 | 19971231 | WO 1997-US10755 | 19970620 |
| | W: AL, AU, | BA, BB | , BG, BR, CA, C | CN, CU, CZ, EE, GE | , GH, HU, IL, IS, |
| | JP, KP, | KR, LC | , LK, LR, LT, I | LV, MG, MK, MN, MX | , NO, NZ, PL, RO, |

```
RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG,
              KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
              GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
              GN, ML, MR, NE, SN, TD, TG
                                               US 1996-671442 A 19960627
     AU 9736414
                        A1
                               19980114
                                               AU 1997-36414
                                                                19970620
                                               US 1996-671442 A 19960627
                                               WO 1997-US10755W 19970620
PATENT FAMILY INFORMATION:
    1996:469927
     PATENT NO.
                        KIND DATE
                                               APPLICATION NO. DATE
     -----
                        ----
                              -----
                                               -----
PI
     US 5536718
                         Α
                               19960716
                                               US 1995-373132
                                                                 19950117
                               19970311
                                               US 1995-458210
     US 5610156
                         Α
                                               US 1995-373132 A319950117
     US 5612334
                         Α
                              19970318
                                               US 1995-460346
                                                                 19950602
                                               US 1995-373132 A319950117
     ZA 9600297
                               19970715
                                               ZA 1996-297
                         Α
                                                              19960115
                                               US 1995-373132 A 19950117
     CA 2210631
                        AA
                              19960725
                                               CA 1996-2210631 19960116
                                               US 1995-373132 A 19950117
                   A1 19960725
                                               WO 1996-US1076 19960116
     WO 9622293
         W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
              NE, SN, TD, TG
                                               US 1995-373132 A 19950117
     AU 9647698
                               19960807
                                               AU 1996-47698 19960116
                         A1
     AU 707982
                        B2
                               19990722
                                               US 1995-373132 A 19950117
                                               WO 1996-US1076 W 19960116
                         A1 19971105
     EP 804438
                                               EP 1996-903698 19960116
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
              SI, LT, LV
                                               US 1995-373132 A 19950117
                                               WO 1996-US1076 W 19960116
     BR 9607182
                                               BR 1996-7182 19960116
                        Α
                               19971111
                                               US 1995-373132 A 19950117
                                               WO 1996-US1076 W 19960116
     CN 1198746
                               19981111
                                               CN 1996-192641
                         Α
                                                                19960116
     CN 1065244
                        В
                               20010502
                                               US 1995-373132 A 19950117
     JP 11500106 .
                        T2
                               19990106
                                               JP 1996-522452 19960116
                                               US 1995-373132 A 19950117
                                               WO 1996-US1076 W 19960116
     IL 116775
                         A1
                               19990817
                                               IL 1996-116775
                                                                19960116
                                               US 1995-373132 A 19950117
                               20000901
     TW 403752
                         В.
                                               TW 1996-85100461 19960116
                                               US 1995-373132 A 19950117
     US 5700796
                                             US 1996-671442
                         Α
                               19971223
                                                                19960627
                                               US 1995-373132 A219950117
     US 5753648
                               19980519
                                               US 1996-672150
                                               US 1995-373132 A219950117
FAN
    1998:42402
     PATENT NO.
                        KIND DATE
                                            APPLICATION NO. DATE
```

| • | | | |
|-----|--------------------------|-----------------------------------|--|
| ΡI | | | WO 1997-US10736 19970620 |
| | | | , CN, CU, CZ, EE, GE, GH, HU, IL, IS, |
| | | | , LV, MG, MK, MN, MX, NO, NZ, PL, RO, , UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, |
| | | RU, TJ, TM | , OA, UZ, VN, IU, ZW, API, AZ, BI, KG, |
| | | | , ZW, AT, BE, CH, DE, DK, ES, FI, FR, |
| | | | , PT, SE, BF, BJ, CF, CG, CI, CM, GA, |
| | GN, ML, | MR, NE, SN, TD, TG | NG 1006 (G0150 > 10060607 |
| | US 5753648 | A 19980519 | US 1996-672150 A 19960627 US 1996-672150 19960627 |
| | 05 5755040 | A 17700317 | US 1995-373132 A219950117 |
| | | A1 19980114 | AU 1997-34063 19970620 |
| | AU 731925 | B2 20010405 | |
| | | | US 1996-672150 A 19960627 |
| | EP 915876 . | A1 19990519 | WO 1997-US10736W 19970620 EP 1997-930167 19970620 |
| | | | , GB, GR, IT, LI, LU, NL, SE, PT, IE, |
| | | LV, FI, RO | |
| | | | US 1996-672150 A 19960627 |
| | BR 9710087 | A 19990810 | WO 1997-US10736W 19970620 BR 1997-10087 19970620 |
| | DR 9/1000/ | . 19990010 | US 1996-672150 A 19960627 |
| | | | WO 1997-US10736W 19970620 |
| | JP 2000510154 | T2 20000808 | JP 1998-503379 19970620 |
| | | | US 1996-672150 A 19960627 |
| FAN | 1998:324820 | | ' WO 1997-US10736W 19970620 |
| | PATENT NO. | KIND DATE | APPLICATION NO. DATE |
| ΡI | US 5753648 | A 19980519 | US 1996-672150 19960627 |
| | 553.551.0 | | US 1995-373132 A219950117 |
| | US 5536718 CA 2258885 | A 19960716 AA 19971231 | US 1995-373132 19950117 CA 1997-2258885 19970620 |
| | G. 2230003 | 7th 19971231 | US 1996-672150 A 19960627 |
| | WO 9749707 | A1 19971231 | WO 1997-US10736 19970620 |
| | | | , CN, CU, CZ, EE, GE, GH, HU, IL, IS, |
| | | | , LV, MG, MK, MN, MX, NO, NZ, PL, RO, , UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, |
| | | RU, TJ, TM | , OA, OZ, VN, IO, ZW, AM, AZ, BI, RG, |
| | RW: GH, KE, | LS, MW, SD, SZ, UG | , ZW, AT, BE, CH, DE, DK, ES, FI, FR, |
| | GB, GR, | IE, IT, LU, MC, NL | , PT, SE, BF, BJ, CF, CG, CI, CM, GA, |
| | GN, ML, | MR, NE, SN, TD, TG | US 1996 672150 N 19960627 |
| | AU 9734063 | A1 19980114 | US 1996-672150 A 19960627 AU 1997-34063 19970620 |
| | AU 731925 | B2 20010405 | 110 1997 01000 1997 0020 |
| | | | US 1996-672150 A 19960627 |
| | EP 915876 | 31 10000510 | WO 1997-US10736W 19970620 |
| | | A1 19990519 CH. DE. DK. ES. FR | EP 1997-930167 19970620 , GB, GR, IT, LI, LU, NL, SE, PT, IE, |
| | | LV, FI, RO | , 52, 50, 11, 21, 20, 60, 60, 11, 15, |
| | | | US 1996-672150 A 19960627 |
| | DD 0710000 | 3 10000010 | WO 1997-US10736W 19970620 |
| | BR 9710087 | A 19990810 | BR 1997-10087 19970620 US 1996-672150 A 19960627 |
| | • | | WO 1997-US10736W 19970620 |
| | CN 1231666 | A 19991013 | CN 1997-197413 19970620 |
| | | | US 1996-672150 A 19960627 |
| | | | |

| JF | 2000510154 | T2 | 20000808 | JΡ | 1998-503379 | 19970620 |
|----|------------|----|----------|----|---------------|----------|
| | | | | US | 1996-672150 A | 19960627 |
| | | | | WO | 1997-US10736W | 19970620 |
| NZ | 332605 | A | 20000929 | NZ | 1997-332605 | 19970620 |
| | | | | US | 1996-672150 A | 19960627 |
| KR | 2000022297 | Α | 20000425 | KR | 1998-710719 | 19981228 |
| | | | | US | 1996-672150 A | 19960627 |

OS MARPAT 128:88934

IT 180416-70-0P 180416-71-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tricyclic benzazepine vasopressin antagonists)

RN 180416-70-0 CAPLUS

CN

3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

RN 180416-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CAINDEX NAME)

GI

The title compds. [I; Y = (CH2)n (n = 0-2), CH(C1-3 alkyl), C(0); AB = CH(C1-3 alkyl)AB (CH2) mNR3, NR3-(CH2) m (m = 1-2; R3 = C(0)Ar; Ar = (un) substituted Ph, 3-pyridyl); Z with two carbon atoms attached = (un)substituted Ph, a 5-membered arom. heterocyclic ring having one heteroatom selected from O,N,S, a 6-membered arom. heterocyclic ring having one N atom, etc.; D, E, F = C, N, which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and oxytocin antagonist activity, and are useful in treating diseases characterized by excess renal reabsorption of water, were prepd. Thus, treatment of 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carboxylic acid with SOC12 followed by reaction of the resulting acid chloride with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine afforded the title compd. II which showed IC50 of 0.033 .mu.M against rat hepatic V1 receptors binding and IC50 of 0.004 .mu.M against rat kidney medullary V2 receptors binding.

```
ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS
L4
     1996:469927 CAPLUS
AN
     125:168035
DN
TI
     Preparation of tricyclic benzazepine vasopressin receptor antagonists
     Albright, Jay D.; Venkatesan, Aranapakam M.; Dusza, John P.; Sum, Fuk-Wah
IN
     American Cyanamid Co., USA
PA
SO
     U.S., 71 pp.
     CODEN: USXXAM
     Patent
DT
LΑ
     English
FAN.CNT 4
                      KIND
                                            APPLICATION NO.
     PATENT NO.
PΙ
     US 5536718
                       Α
                            19960716
                                            US 1995-373132
                                                             19950117
     US 5610156
                                            US 1995-458210
                       Α
                            19970311
                                                             19950602
                                            UŚ 1995-373132 A319950117
     US 5612334
                                            US 1995-460346
                       Α
                            19970318
                                                             19950602
                                            US 1995-373132 A319950117
     ZA 9600297
                            19970715
                                            ZA 1996-297
                                                             19960115
                                            US 1995-373132 A 19950117
     CA 2210631
                       AA
                            19960725
                                            CA 1996-2210631 19960116
                                            US 1995-373132 A 19950117
                                                            19960116
     WO 9622293
                            19960725
                                            WO 1996-US1076
                       A1
         W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG,
             KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO,
             SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
             IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
             NE, SN, TD, TG
                                            US 1995-373132 A 19950117
     AU 9647698
                       A1
                            19960807
                                            AU 1996-47698
                                                             19960116
     AU 707982
                       B2
                            19990722
                                            US 1995-373132 A 19950117
                                            WO 1996-US1076 W 19960116
     EP 804438
                      · A1
                                            EP 1996-903698 19960116
                            19971105
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
             SI, LT, LV
                                            US 1995-373132 A 19950117
                                            WO 1996-US1076 W 19960116
     BR 9607182
                            19971111
                                            BR 1996-7182
                                                             19960116
                                            US 1995-373132 A 19950117
                                            WO 1996-US1076 W 19960116
     CN 1198746
                            19981111
                                            CN 1996-192641
                       Α
                                                             19960116
     CN 1065244
                       В
                            20010502
                                            US 1995-373132 A 19950117
     JP 11500106
                       T2
                            19990106
                                            JP 1996-522452
                                                             19960116
                                            US 1995-373132 A 19950117
                                            WO 1996-US1076 W 19960116
    IL 116775
                            19990817
                       A1
                                            IL 1996-116775
                                                             19960116
                                            US 1995-373132 A 19950117
     TW 403752
                            20000901
                                            TW 1996-85100461 19960116
                                            US 1995-373132 A 19950117
                                            US 1996-671442
     US 5700796
                       Α
                            19971223.
                                                             19960627
                                            US 1995-373132 A219950117
     US 5753648
                                            US 1996-672150
                            19980519
                                                             19960627
                                            US 1995-373132 A219950117
PATENT FAMILY INFORMATION:
```

| FAN | 1998:8260 PATENT NO. | KIND DATE | · APPLICATION NO. DATE |
|-----|--------------------------|--------------------------------|---|
| | | | |
| ΡI | | A 19971223 | US 1995-373132 A219950117 |
| | US 5536718 WO 9749708 | A 19960716 A1 19971231 | US 1995-373132 19950117 WO 1997-US10755 19970620 |
| | | | CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, |
| | | | TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, |
| | | RU, TJ, TM | UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, |
| | GB, GR, | IE, IT, LU, MC, | NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, |
| | GN, ML, | MR, NE, SN, TD, | TG US 1996-671442 A 19960627 |
| | AU 9736414 | A1 19980114 | |
| | | · | US 1996-671442 A 19960627 WO 1997-US10755W 19970620 |
| FAN | 1998:42402 PATENT NO. | KIND DATE | APPLICATION NO. DATE |
| DT | | | |
| PI | WO 9749707 W: AL, AU, | | WO 1997-US10736 19970620 CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, |
| | | | LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, |
| | KZ, MD, | RU, TJ, TM | |
| | | | UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, |
| | | MR, NE, SN, TD, | |
| | US 5753648 | A 19980519 | US 1996-672150 ·19960627 |
| | AU 9734063 | A1 19980114 | US 1995-373132 A219950117 AU 1997-34063 19970620 |
| | AU 731925 | B2 20010405 | US 1996-672150 A 19960627 |
| | | • | WO 1997-US10736W 19970620 |
| | | A1 19990519 CH, DE, DK, ES, | EP 1997-930167 19970620 FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, |
| | | LV, FI, RO | US 1996-672150 A 19960627 |
| | | | WO 1997-US10736W 19970620 |
| | BR 9710087 | A 19990810 | BR 1997-10087 19970620 US 1996-672150 A 19960627 |
| | JP 2000510154 | T2 20000808 | WO 1997-US10736W 19970620 JP 1998-503379 19970620 |
| | 01 2000310134 | 12 20000808 | US 1996-672150 A 19960627 |
| FAN | 1998:324820 | | WO 1997-US10736W 19970620 |
| | PATENT NO. | KIND DATE | APPLICATION NO. DATE |
| PI | US 5753648 | | US 1996-672150 19960627 |
| | US 5536718 | A 19960716 | US 1995-373132 A219950117 US 1995-373132 19950117 |
| | CA 2258885 | AA 19971231 | CA 1997-2258885 19970620 |
| | WO 9749707 | | |
| | | | CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, |
| | .,, | 11 | , , ,,,,,,, |

RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG US 1996-672150 A 19960627 AU 9734063 19980114 AU 1997-34063 . 19970620 **A1** AU 731925 B2 20010405 US 1996-672150 A 19960627 WO 1997-US10736W 19970620 EP 915876 19990519 EP 1997-930167 Α1 19970620 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO US 1996-672150 A 19960627 WO 1997-US10736W 19970620 BR 9710087 19990810 BR 1997-10087 Α 19970620 US 1996-672150 A 19960627 WO 1997-US10736W 19970620 CN 1231666 Α 19991013 CN 1997-197413 19970620 US 1996-672150 A 19960627 JP 2000510154 19970620 T2 20000808 JP 1998-503379 US 1996-672150 A 19960627 WO 1997-US10736W 19970620 NZ 332605 Α 20000929 NZ 1997-332605 19970620 US 1996-672150 A 19960627 KR 1998-710719 KR 2000022297 20000425 Α 19981228 US 1996-672150 À 19960627

OS MARPAT 125:168035

IT 180416-70-0P 180416-71-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tricyclic benzazepine vasopressin receptor antagonists)

RN 180416-70-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-(methylamino)-N-[4-(5H-pyrrolo[2,1-

c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

RN 180416-71-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

GI

$$Z = \begin{bmatrix} H_2 \\ C \\ N \end{bmatrix} = \begin{bmatrix} H_2 \\ F \\ A - B \end{bmatrix} I$$
 CF_3

II

- AB The title compds. [I; Z = fused (un)substituted Ph ring; AB = CH2NR3, R3NCH2; R3 = (un)substituted arylcarbonyl; DEF ring = 5-member N-contg. (un)substituted heterocyclic ring), which exhibit antagonist activity at V1 and/or V2 receptors and exhibit in-vivo vasopressin antagonist activity, useful in treating diseases characterized by excess renal reabsorption of water (e.g., brain edema, cirrhosis, hyponatremia, brain edema, congestive heart failure, etc.), are prepd. Thus, 2-chloro-4-[(4'-trifluoromethyl)[1,1'-biphenyl-2-carbonyl]amino]benzoyl chloride was reacted with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4-]benzodiazepine, producing benzodiazepine II, which demonstrated a rat kidney-derived V1 receptor IC50 of 41% at 1 .mu.M and 92% for the V2 receptor at 10 .mu.M.
- L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS
- AN 1994:298580 CAPLUS
- DN 120:298580
- TI Reactions of 5-(p-anisyl)-2-methyl-7-(p-tolyl)-4H-pyrido[2,3-d][1,3]oxazin-4-one
- AU Madkour, Hassan M. F.; Salem, Mounir A. I.; Abdel-Rahman, Taha M.; Azab, Mohamed E.
- CS Fac. Sci., Ain Shams Univ., Abbassia, Egypt
- SO Heterocycles (1994), 38(1), 57-69 CODEN: HTCYAM; ISSN: 0385-5414
- DT Journal
- LA English
- IT 154778-17-3P
 - RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
- RN 154778-17-3 CAPLUS
- CN 3-Pyridinecarboxamide, 2-(acetylamino)-4-(4-methoxyphenyl)-N,6-bis(4methylphenyl)- (9CI) (CA INDEX NAME)